WW International swings to $15.1M profit in Q3 2026

WW narrowed its fiscal 2026 outlook to revenue of $610 million–$630 million and Adjusted EBITDA of $110 million–$115 million.

Available on EDGAR 11/05/2026 - 07:07 AM EST Accepted by SEC EDGAR 11/05/2026 - 07:01 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

WW International, Inc. (WW) reported third-quarter fiscal 2026 revenue of $152.9 million, down 11.2% year over year. Clinical Subscription Revenue was $38.0 million, up 47.6%, while total end-of-period subscribers were 2.296 million, down 23.1%. Clinical subscribers increased 40.4% to 174,000; Behavioral subscribers fell 25.9% to 2.122 million.

WW reported net income of $15.1 million, compared with a $57.5 million net loss in Q3 2025. Adjusted EBITDA, a non-GAAP measure, was $51.7 million with a 33.8% margin, versus $42.8 million and 24.9% a year earlier. Monthly Subscription Revenue Per Average Subscriber was $21.17, up 14.3% year over year. Cash and cash equivalents were $126.4 million at September 30, 2026, versus $160.3 million at December 31, 2025; long-term debt, net, was $424.0 million and $465.5 million on those dates.

WW narrowed fiscal 2026 guidance to revenue of $610 million to $630 million and Adjusted EBITDA of $110 million to $115 million. It reported Q3 marketing expenses of $33.1 million, or 21.6% of revenue, compared with $48.4 million, or 28.1%, a year earlier.

3 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

How the balance works

Positive

• Moderate pointClinical Subscription Revenue rose 47.6% to $38.0 million year over year.
• Moderate pointWW reported $15.1 million of net income versus a $57.5 million loss.
• Moderate pointAdjusted EBITDA reached $51.7 million, versus $42.8 million a year earlier.

Negative

• Moderate pointQ3 revenue fell 11.2% year over year to $152.9 million.
• Moderate pointEnd-of-period subscribers declined 23.1% year over year to 2.296 million.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Revenue: $152.9 million Clinical Subscription Revenue: $38.0 million Net income: $15.1 million +5 more

8 metrics

Revenue $152.9 million Q3 fiscal 2026; down 11.2% year over year

Clinical Subscription Revenue $38.0 million Q3 fiscal 2026; up 47.6% year over year

Net income $15.1 million Q3 fiscal 2026; compared with a $57.5 million net loss in Q3 2025

Adjusted EBITDA $51.7 million Q3 fiscal 2026; $42.8 million in Q3 2025

End-of-period subscribers 2.296 million September 30, 2026; down 23.1% year over year

Clinical end-of-period subscribers 174,000 subscribers September 30, 2026; up 40.4% year over year

Fiscal 2026 revenue guidance $610 million to $630 million Narrowed full-year guidance

Fiscal 2026 Adjusted EBITDA guidance $110 million to $115 million Narrowed full-year guidance

Key Terms

Adjusted EBITDA, Clinical Subscription Revenue, End of Period Subscribers, Monthly Subscription Revenue Per Average Subscriber, +2 more

6 terms

Adjusted EBITDA financial

"$51.7 million of Adjusted EBITDA"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

Clinical Subscription Revenue financial

"Clinical Subscription Revenue of $38 million"

End of Period Subscribers financial

"The “End of Period Subscribers” metric reports"

Monthly Subscription Revenue Per Average Subscriber financial

"Monthly Subscription Revenue Per Average Subscriber metric"

Fresh Start Accounting financial

"applied fresh start accounting"

Fresh start accounting is an accounting reset that occurs after a company emerges from a major restructuring or bankruptcy, where assets and liabilities are revalued to current fair values and a new equity base is recorded. Like wiping a chalkboard and writing a new starting score, it gives investors a clearer baseline for future performance but can make past results hard to compare and often changes reported profits, asset values and shareholder stakes.

constant currency financial

"presentation of results on a constant currency basis"

Constant currency is a way of measuring financial results that removes the effects of changes in currency exchange rates. It allows for a clearer comparison of a company's performance over time by showing what the numbers would look like if exchange rates had stayed the same. This helps investors understand whether growth comes from actual business improvements or just currency fluctuations.

Earnings Snapshot

Revenue: $152.9 million · Guidance included

Third quarter of fiscal 2026 ended September 30, 2026

Revenue $152.9 million -11.2% year over year

Clinical Subscription Revenue $38.0 million +47.6% year over year

Net income $15.1 million Q3 2025: net loss of $57.5 million

Adjusted EBITDA $51.7 million Q3 2025: $42.8 million

End-of-period subscribers 2.296 million -23.1% year over year

Guidance

Narrowed fiscal 2026 guidance: revenue of $610 million to $630 million and Adjusted EBITDA of $110 million to $115 million.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was WW's revenue in Q3 2026?

WW reported $152.9 million in revenue for Q3 2026, down 11.2% year over year. Clinical Subscription Revenue was $38.0 million, up 47.6% year over year.

Did WW make a profit in Q3 2026?

WW reported net income of $15.1 million, compared with a $57.5 million net loss in Q3 2025. Adjusted EBITDA was $51.7 million, with a 33.8% margin.

What was WW's monthly subscription revenue per average subscriber in Q3 2026?

Monthly Subscription Revenue Per Average Subscriber was $21.17, up 14.3% year over year. The Behavioral figure was $17.21, up 5.0%, while the Clinical figure was $68.25, down 0.4%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0000105319 0000105319 2026-11-05 2026-11-05 0000105319 stpr:VA 2026-11-05 2026-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 5, 2026

WW INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Virginia		001-16769		11-6040273
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

18 West 18th Street, 7th Floor, New York, New York		10011
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 589-2700

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, no par value		WW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 5, 2026, WW International, Inc. issued a press release and a Shareholder Letter announcing its financial results for its fiscal quarter ended September 30, 2026. Copies of the press release and the Shareholder Letter are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated herein by reference.

The information contained in Item 2.02 of this Current Report on Form 8-K, including the text of the press release attached as Exhibit 99.1 and the Shareholder Letter attached as Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information contained in Items 2.02 and 9.01 of this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document or filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit		Description
Exhibit 99.1		Press Release dated November 5, 2026.
Exhibit 99.2		Shareholder Letter dated November 5, 2026.
Exhibit 104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				WW INTERNATIONAL, INC.
DATED: November 5, 2026				By:		/s/ Felicia DellaFortuna
				Name:		Felicia DellaFortuna
				Title:		Chief Financial Officer

3

Exhibit 99.1

Weight Watchers Announces Third Quarter 2026 Results

Revenue of $153 million; Clinical Subscription Revenue of $38 million, up 48% year-over-year

2.3 million Total End of Period Subscribers; 40% year-over-year Clinical End of Period Subscriber growth to 174 thousand and 16% year-over-year Core+ End of Period Subscriber growth to 546 thousand

Positive Net Income of $15.1 million, representing a 9.9% Net Income Margin; Adjusted EBITDA¹ of $51.7 million, representing a 33.8% Adjusted EBITDA Margin¹

NEW YORK (November 5, 2026) – WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the third quarter of fiscal 2026 ended September 30, 2026² in this Earnings Press Release and a Shareholder Letter issued today and posted on the Company’s Corporate Website.

“Since joining Weight Watchers on October 1, I made it my priority to listen to our members, coaches, clinicians, registered dietitians, and colleagues. Through these conversations, two core truths emerged: weight loss is personal, and the support people need changes along the way,” said Stephen Bye, President and Chief Executive Officer. “Our strength lies in the commitment of our team and our ability to bring together science-backed behavioral programs, clinical care, and the human connection that has defined this brand for more than 60 years. My focus is on strengthening our member experience, improving our products and applications, and building on the work already underway.”

“We remained focused on strengthening our two higher-value product offerings and proactively calibrating our spend across our portfolio,” said Felicia DellaFortuna, Chief Financial Officer. “That approach helped drive sustained progress in these offerings with four quarters of quarter-over-quarter growth in Core+ subscribers, and the largest year-over-year Clinical Subscription Revenue growth percentage in any quarter of 2026 to date. That top-line progress, combined with our continued disciplined investment, directly translated to $51.7 million of Adjusted EBITDA¹, representing a 33.8% Adjusted EBITDA Margin¹.”

Q3 Business Updates

• Q3 Revenue was $152.9 million, down 11% year-over-year. Clinical Subscription Revenue grew 48% year-over-year to $38.0 million and represented 25% of total Revenue, up from 15% in Q3 2025.

• Q3 Total End of Period Subscribers were 2.3 million. Core+ End of Period Subscribers reached 546 thousand, up 16% year-over-year, marking a fourth consecutive quarter of sequential subscriber growth in our higher-value Behavioral membership tier. Clinical End of Period Subscribers were 174 thousand, up 40% year-over-year.

• Monthly Subscription Revenue Per Average Subscriber was $21.17, up 14% year-over-year, reflecting the growing share of our Clinical business and continued growth in Core+ Subscribers.

• Q3 Gross Margin was 71.1% and Adjusted Gross Margin¹ was 74.6%, both the highest of the first three quarters of 2026, compared with 72.1% and 75.1%, respectively, in Q3 2025.

• Net Income for Q3 was $15.1 million, compared to a Net Loss of $57.5 million in Q3 2025. Q3 Adjusted EBITDA¹ increased 21% year-over-year to $51.7 million from $42.8 million in Q3 2025, reflecting continued expense discipline and lower marketing relative to Q3 2025, which included investment to support a product launch.

• Cash and Cash Equivalents were $126.4 million at quarter end, up from $101.5 million at the end of Q2 2026.

Fiscal 2026 Guidance

The Company narrowed its previously provided full year fiscal 2026 guidance.

• Revenue guidance of $625 million to $630 million, compared to the prior range of $620 million to $635 million.

• Adjusted EBITDA¹ guidance of $110 million to $115 million, compared to the prior range of $105 million to $115 million.

Third Quarter 2026 Conference Call and Webcast

The Company has scheduled a conference call today at 8:30 a.m. ET to discuss results. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days.

1

¹Statement regarding Non-GAAP Financial Measures

To supplement the Company’s consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has disclosed non-GAAP financial measures of operating results that exclude or adjust certain items. The Company presents in this release non-GAAP financial measures, including earnings before interest, taxes, depreciation and amortization expenses and share-based compensation expense (“EBITDA”); and for each period presented, EBITDA adjusted, as applicable, for (a) goodwill and other indefinite-lived intangible asset impairments, (b) reorganization items, net related to the Company’s emergence from its Chapter 11 financial reorganization, (c) gain on extinguishment of debt, (d) transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization, (e) net restructuring charges associated with the previously disclosed 2025, 2024, and 2023 restructuring plans, (f) expenses in connection with the management of certain executive matters and (g) other items such as the impact of foreign exchange gains and losses as indicated in the reconciliations below that management believes are not indicative of ongoing operations (“Adjusted EBITDA”). The Company also presents gross profit, gross margin, marketing expenses, selling, general and administrative expenses, and product development expenses on a non-GAAP basis that adjusts for similar items, as further indicated in the reconciliations below.

As exchange rates are an important factor in understanding period-to-period comparisons, the Company believes in certain cases the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand the Company’s operating results and evaluate the Company’s performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. The Company uses results on a constant currency basis as one measure to evaluate the Company’s performance. In this press release, the Company calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. The Company generally refers to such amounts calculated on a constant currency basis as excluding or adjusting for the impact of foreign currency or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP and are not meant to be considered in isolation. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Management believes these non-GAAP financial measures provide useful supplemental information to investors regarding the performance of the Company’s business and are useful for period-over-period comparisons of the performance of the Company’s business. While the Company believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies. See “Reconciliation of Non-GAAP Financial Measures” in this release and reconciliations, if any, included elsewhere in this release for a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures.

2

A reconciliation of the forward-looking full year Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of the Company’s control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

²Fresh Start Accounting and Predecessor and Successor Periods

In connection with the Company’s emergence from its financial reorganization process on June 24, 2025, the Company applied fresh start accounting which resulted in Successor and Predecessor financial statement presentation. References to “Successor” relate to the Company’s operations for the three and nine months ended September 30, 2026 and the period from June 25, 2025 through September 30, 2025. References to “Predecessor” relate to the Company’s operations for the period December 29, 2024 through June 24, 2025. Accordingly, the consolidated financial statements after June 24, 2025 are not comparable with the consolidated financial statements as of or prior to that date.

Definitions

“Behavioral” business refers to providing subscriptions to the Company’s digital product offerings with the option to upgrade to unlimited access to the Company’s workshops and certain tailored versions of its behavior change program.

“Clinical” business refers to providing subscriptions to the Company’s clinical product offerings provided by Weight Watchers Clinic and third parties combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops and certain tailored versions of its behavior change program.

“Revenue” - “Subscription Revenue” consists of the aggregate of: (a) “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. In addition, “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

3

“Incoming Subscribers” - “Subscribers” refer to Behavioral subscribers and Clinical subscribers who participate in recurring bill programs in Company-owned operations. The “Incoming Subscribers” metric reports Subscribers in Company-owned operations at a given period start. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“End of Period Subscribers” - The “End of Period Subscribers” metric reports Subscribers in Company-owned operations at a given period end. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“Monthly Subscription Revenue Per Average Subscriber” (“ARPU”) - The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for both quarterly and year-to-date periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective quarterly or year-to-date period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period. Management utilizes this metric to consider revenue growth and trends on a per subscriber basis.

About Weight Watchers

Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

4

This press release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any statements about the Company’s plans, strategies, objectives, initiatives, and prospects. The Company generally uses the words “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “aim” and similar expressions in this press release to identify forward-looking statements. The Company bases these forward-looking statements on its current views with respect to future events and financial performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, including, among other things: the Company’s recent emergence from bankruptcy, which could adversely affect its business and relationships and subjects us to risks and uncertainties; competition from other weight management and health and wellness industry participants or the development of more effective or more favorably perceived weight management methods; the Company’s failure to continue to retain and grow its subscriber base; the Company’s ability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss market; the Company’s ability to continue to develop new, innovative services and products and enhance its existing services and products or the failure of its services, products or brands to continue to appeal to the market, or its ability to successfully expand into new channels of distribution or respond to consumer trends or sentiment; the Company’s ability to successfully implement strategic initiatives; the effectiveness and efficiency of its advertising and marketing programs across multiple platforms, including digital marketing and social media platforms; the impact on the Company’s reputation of actions taken by its franchisees, licensees, suppliers, affiliated provider entities, PCs’ healthcare professionals, and other partners; the recognition of asset impairment charges; the loss of key personnel, strategic partners or consultants or failure to effectively manage and motivate the Company’s workforce; the Company’s chief executive officer transition; the Company’s ability to successfully make acquisitions or enter into collaborations or joint ventures, including its ability to successfully integrate, operate or realize the anticipated benefits of such businesses; uncertainties related to a downturn in general economic conditions or consumer confidence, including as a result of the existing inflationary environment, changes in tariffs and escalating trade tensions, rising interest rates, the potential impact of political and social unrest and increased volatility in the credit and capital markets; the seasonal nature of the Company’s business; the Company’s failure to maintain effective internal control over financial reporting; the impact of events that impede accessing resources or discourage or impede people from gathering with others; the early termination by us of leases; the inability to renew certain of the Company’s licenses, or the inability to do so on terms that are favorable to us; the dependence of the Company’s payments system on third-party service providers; the impact of the Company’s exposure to variable rate indebtedness; the ability to generate sufficient cash to service the Company’s debt and satisfy its other liquidity requirements; uncertainties regarding the satisfactory operation of the Company’s technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compliance with evolving privacy laws and regulations; the Company’s ability to successfully integrate and use artificial intelligence in its business; the Company’s ability to enforce its intellectual property rights both domestically and internationally, as well as the impact of its involvement in any claims related to intellectual property rights; the impact of existing and future laws and regulations; risks related to the Company’s exposure to extensive and complex healthcare laws and regulations; the outcomes of litigation or regulatory actions; risks and uncertainties associated with the Company’s international operations, including regulatory, economic, political, social, intellectual property, and foreign currency risks, which risks may be exacerbated as a result of war and terrorism; the Company’s ability to engage in share repurchases and pay cash dividends in the foreseeable future; risks related to the actions of activist shareholders and anti-takeover provisions in the Company’s articles of incorporation and bylaws; risks related to the actions of the Company’s shareholders and the exclusive forum provisions in its articles of incorporation; the possibility that the Company could fail to maintain the listing of the Company’s common stock on Nasdaq; and other risks and uncertainties, including those included in this press release and those detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”) (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause the Company’s results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, the Company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this press release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the Company’s filings with the SEC (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com).

For investor inquiries, please contact:

Anna Kate Heller

WeightWatchers@icrinc.com

For media inquiries, please contact:

Melissa Garbayo

melissa.garbayo@ww.com

5

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

UNAUDITED

		Successor
		September 30, 2026				December 31, 2025
ASSETS
CURRENT ASSETS
Cash and cash equivalents		$	126,442			$	160,279
Restricted cash			5,796				6,298
Receivables (net of allowances: September 30, 2026 - $2,132 and December 31, 2025 - $1,651)			11,977				16,378
Prepaid income taxes			3,728				8,097
Prepaid marketing and advertising			2,050				9,275
Prepaid expenses and other current assets			11,489				13,277
TOTAL CURRENT ASSETS			161,482				213,604
Property and equipment, net			6,316				8,115
Operating lease assets			1,803				2,933
Goodwill			199,858				200,135
Other intangible assets, net			446,794				490,664
Deferred income taxes			16,209				16,482
Other noncurrent assets			14,871				14,825
TOTAL ASSETS		$	847,333			$	946,758
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Portion of operating lease liabilities due within one year		$	918			$	1,260
Accounts payable			19,644				9,212
Salaries and wages payable			20,100				34,375
Accrued marketing and advertising			8,055				22,985
Accrued interest			892				1,084
Other accrued liabilities			18,911				23,049
Income taxes payable			1,644				6,006
Deferred revenue			21,943				28,565
TOTAL CURRENT LIABILITIES			92,107				126,536
Long-term debt, net			423,970				465,466
Long-term operating lease liabilities			1,159				1,893
Deferred income taxes			36,253				34,021
Other noncurrent liabilities			576				771
TOTAL LIABILITIES			554,065				628,687
EQUITY
Successor common stock, $0 par value; 1,000,000 shares authorized; 9,999 shares issued at September 30, 2026 and 9,992 shares issued at December 31, 2025			380,136				378,777
Accumulated deficit			(84,913	)			(62,095	)
Accumulated other comprehensive (loss) income			(1,955	)			1,389
TOTAL EQUITY			293,268				318,071
TOTAL LIABILITIES AND TOTAL EQUITY		$	847,333			$	946,758

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

UNAUDITED

		Successor
		Three Months Ended September 30, 2026				Three Months Ended September 30, 2025
Subscription revenue, net (1)		$	151,960			$	170,929
Other revenue, net (2)			941				1,162
Revenue, net			152,901				172,091
Cost of subscription revenue (3)			44,144				47,908
Cost of other revenue			65				72
Cost of revenue			44,209				47,980
Gross profit			108,692				124,111
Marketing expenses			33,094				48,404
Product development expenses			5,235				7,550
Selling, general and administrative expenses			33,849				60,122
Operating income			36,514				8,035
Interest expense			10,861				12,052
Other (income) expense, net			(147	)			342
Income (loss) before income taxes			25,800				(4,359	)
Provision for income taxes			10,692				53,157
Net income (loss)		$	15,108			$	(57,516	)
Earnings (net loss) per share
Basic		$	1.51			$	(5.76	)
Diluted		$	1.51			$	(5.76	)
Weighted average common shares outstanding
Basic			9,999				9,987
Diluted			10,021				9,987

Note: Totals may not sum due to rounding. 

⁽¹⁾ “Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings.

⁽²⁾  “Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

⁽³⁾  “Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company’s Behavioral and Clinical services.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

UNAUDITED

		Successor								Predecessor
		Nine Months Ended September 30, 2026				Period from June 25, 2025 through September 30, 2025				Period from December 29, 2024 through June 24, 2025
Subscription revenue, net (1)		$	480,710			$	183,007			$	360,953
Other revenue, net (2)			2,777				1,251				2,615
Revenue, net			483,487				184,258				363,568
Cost of subscription revenue (3)			141,603				51,166				100,026
Cost of other revenue			377				72				158
Cost of revenue			141,980				51,238				100,184
Gross profit			341,507				133,020				263,384
Marketing expenses			173,903				51,188				110,871
Product development expenses			19,768				8,236				25,281
Selling, general and administrative expenses			132,286				62,975				78,480
Franchise rights acquired impairments			—				—				27,549
Operating income			15,550				10,621				21,203
Reorganization items, net			—				—				(1,143,918	)
Interest expense			33,925				12,975				38,664
Gain on extinguishment of debt			(4,612	)			—				—
Other (income) expense, net			(1,305	)			1,274				6,685
(Loss) income before income taxes			(12,458	)			(3,628	)			1,119,772
Provision for income taxes			10,360				52,634				1,669
Net (loss) income		$	(22,818	)		$	(56,262	)		$	1,118,103
(Net loss) earnings per share
Basic		$	(2.28	)		$	(5.63	)		$	13.93
Diluted		$	(2.28	)		$	(5.63	)		$	13.80
Weighted average common shares outstanding
Basic			9,998				9,987				80,271
Diluted			9,998				9,987				80,998

Note: Totals may not sum due to rounding.

⁽¹⁾ “Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings.

⁽²⁾  “Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

⁽³⁾  “Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company’s Behavioral and Clinical services.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

UNAUDITED

		Successor								Predecessor
		Nine Months Ended September 30, 2026				Period from June 25, 2025 through September 30, 2025				Period from December 29, 2024 through June 24, 2025
Operating activities:
Net (loss) income		$	(22,818	)		$	(56,262	)		$	1,118,103
Adjustments to reconcile net (loss) income to cash provided by (used for) operating activities:
Depreciation and amortization			64,851				27,174				14,201
Amortization of deferred financing costs and debt (premium) discount, net			(76	)			(26	)			1,766
Impairment of franchise rights acquired			—				—				27,549
Impairment of long-lived assets			3				—				97
Share-based compensation expense			1,324				—				4,032
Deferred tax provision			1,970				1,064				26,232
Allowance for doubtful accounts			48				(513	)			(1,131	)
Foreign currency exchange rate (gain) loss			(1,206	)			1,298				6,717
Non-cash reorganization items, net			—				—				(1,176,532	)
Gain on extinguishment of debt			(4,612	)			—				—
Changes in cash due to:
Receivables			4,169				(2,245	)			4,280
Prepaid expenses			13,537				39,934				(31,281	)
Accounts payable			10,466				1,454				(8,237	)
Accrued liabilities			(33,680	)			(14,623	)			15,084
Deferred revenue			(6,397	)			(2,220	)			(2,914	)
Other long term assets and liabilities, net			(191	)			(11	)			(2,234	)
Income taxes			(4,349	)			13,394				(30,155	)
Cash provided by (used for) operating activities			23,039				8,418				(34,423	)
Investing activities:
Capital expenditures			—				(6	)			(87	)
Capitalized software and website development expenditures			(18,899	)			(3,678	)			(6,253	)
Cash paid for acquisitions, net of cash acquired			—				(1,020	)			—
Other items, net			—				(3	)			(1	)
Cash used for investing activities			(18,899	)			(4,707	)			(6,341	)
Financing activities:
Borrowings on revolving credit facility			—				—				171,341
Financing costs			—				—				(1,298	)
Payments on long-term debt			(36,808	)			—				—
Taxes paid related to net share settlement of equity awards			—				—				(145	)
Cash paid for acquisitions			—				—				(16,000	)
Cash (used for) provided by financing activities			(36,808	)			—				153,898
Effect of exchange rate changes on cash and cash equivalents and restricted cash			(1,671	)			235				3,966
Net (decrease) increase in cash and cash equivalents and restricted cash			(34,339	)			3,946				117,100
Cash and cash equivalents and restricted cash, beginning of period			166,577				173,620				56,520
Cash and cash equivalents and restricted cash, end of period		$	132,238			$	177,566			$	173,620

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

														Variance
		Successor																2026 Constant Currency vs 2025
		Three Months Ended September 30, 2026								Three Months Ended September 30, 2025				2026 vs 2025
		GAAP				Constant Currency				GAAP
Selected Financial Data
Revenue (1)		$	152,901			$	153,270			$	172,091				(11.2	%)			(10.9	%)
Behavioral Subscription Revenue (2)		$	113,923			$	114,286			$	145,152				(21.5	%)			(21.3	%)
Clinical Subscription Revenue (3)		$	38,037			$	38,037			$	25,777				47.6	%			47.6	%
Subscription Revenue (4)		$	151,960			$	152,323			$	170,929				(11.1	%)			(10.9	%)
Other Revenue (5)		$	941			$	947			$	1,162				(19.0	%)			(18.5	%)

Note: Totals may not sum due to rounding.

⁽¹⁾  “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

⁽²⁾  “Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings.

⁽³⁾  “Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings.

⁽⁴⁾  “Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue.

⁽⁵⁾  “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

														Variance
														2026 vs 2025 Combined				2026 Constant Currency vs 2025 Combined
		Successor
		Nine Months Ended September 30, 2026								Nine Months Ended September 30, 2025
		GAAP				Constant Currency				Combined (1)
Selected Financial Data
Revenue (2)		$	483,487			$	478,801			$	547,826				(11.7	%)			(12.6	%)
Behavioral Subscription Revenue (3)		$	363,933			$	359,291			$	458,133				(20.6	%)			(21.6	%)
Clinical Subscription Revenue (4)		$	116,777			$	116,778			$	85,827				36.1	%			36.1	%
Subscription Revenue (5)		$	480,710			$	476,070			$	543,960				(11.6	%)			(12.5	%)
Other Revenue (6)		$	2,777			$	2,732			$	3,866				(28.2	%)			(29.3	%)

Note: Totals may not sum due to rounding.

⁽¹⁾  These amounts combine the revenue of the Successor and Predecessor periods for comparability purposes. Although the Successor and Predecessor have a different accounting basis due to the application of fresh start accounting, none of the fresh start accounting adjustments impact revenue. Therefore, the combined revenue amounts presented are consistent with a pro forma presentation under Article 11 of Regulation S-X as if fresh start accounting was applied at the beginning of the first period presented.

⁽²⁾  “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

⁽³⁾  “Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings.

⁽⁴⁾  “Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings.

⁽⁵⁾  “Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue.

⁽⁶⁾  “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

OPERATIONAL STATISTICS

(IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER)

UNAUDITED

		Successor
		Three Months Ended September 30, 2026								Three Months Ended September 30, 2025				Variance				Variance
						(Constant Currency)												(Constant Currency)
Incoming Subscribers (1)
Incoming Behavioral Subscribers			2,291				N/A				3,040				(24.6	%)			N/A
Incoming Clinical Subscribers			197				N/A				127				55.7	%			N/A
Incoming Subscribers			2,489				N/A				3,167				(21.4	%)			N/A
End of Period Subscribers (2)
End of Period Behavioral Subscribers			2,122				N/A				2,862				(25.9	%)			N/A
End of Period Clinical Subscribers			174				N/A				124				40.4	%			N/A
End of Period Subscribers			2,296				N/A				2,986				(23.1	%)			N/A
Monthly Subscription Revenue Per Average Subscriber (3)
Monthly Behavioral Subscription Revenue Per Average Subscriber		$	17.21			$	17.26			$	16.39				5.0	%			5.3	%
Monthly Clinical Subscription Revenue Per Average Subscriber		$	68.25			$	68.25			$	68.52				(0.4	%)			(0.4	%)
Monthly Subscription Revenue Per Average Subscriber		$	21.17			$	21.22			$	18.52				14.3	%			14.6	%

Note: Totals may not sum due to rounding.

⁽¹⁾  The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start.

⁽²⁾  The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end.

⁽³⁾  The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for quarterly periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective quarterly period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

OPERATIONAL STATISTICS

(IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER)

UNAUDITED

		Successor								Combined
		Nine Months Ended September 30, 2026								Nine Months Ended September 30, 2025				Variance				Variance
						(Constant Currency)												(Constant Currency)
Incoming Subscribers (1)
Incoming Behavioral Subscribers			2,631				N/A				3,244				(18.9	%)			N/A
Incoming Clinical Subscribers			130				N/A				92				41.9	%			N/A
Incoming Subscribers			2,761				N/A				3,336				(17.2	%)			N/A
End of Period Subscribers (2)
End of Period Behavioral Subscribers			2,122				N/A				2,862				(25.9	%)			N/A
End of Period Clinical Subscribers			174				N/A				124				40.4	%			N/A
End of Period Subscribers			2,296				N/A				2,986				(23.1	%)			N/A
Monthly Subscription Revenue Per Average Subscriber (3)
Monthly Behavioral Subscription Revenue Per Average Subscriber		$	17.00			$	16.78			$	16.43				3.5	%			2.2	%
Monthly Clinical Subscription Revenue Per Average Subscriber		$	74.33			$	74.33			$	78.30				(5.1	%)			(5.1	%)
Monthly Subscription Revenue Per Average Subscriber		$	20.92			$	20.72			$	18.71				11.8	%			10.7	%

Note: Totals may not sum due to rounding.

⁽¹⁾  The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start.

⁽²⁾  The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end.

⁽³⁾  The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for year-to-date periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective year-to-date period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

		Successor
		Three Months Ended September 30, 2026																Three Months Ended September 30, 2025
		Gross Profit				Marketing Expenses				Product Development Expenses				Selling, General, and Administrative Expenses				Gross Profit				Marketing Expenses				Product Development Expenses				Selling, General, and Administrative Expenses
GAAP		$	108,692			$	33,094			$	5,235			$	33,849			$	124,111			$	48,404			$	7,550			$	60,122
% of Revenue			71.1	%			21.6	%			3.4	%			22.1	%			72.1	%			28.1	%			4.4	%			34.9	%
Adjustments:
Transaction Costs (1)		$	—			$	—			$	—			$	—			$	—			$	—			$	—			$	(9,126	)
Depreciation and Amortization Expenses			5,353				—				—				(7,696	)			5,135				—				(58	)			(20,301	)
Restructuring Charges (2)			—				—				—				—				23				—				—				(99	)
Share-based Compensation Expense			0				(20	)			(99	)			(586	)			—				—				—				—
Executive Related Costs (3)			—				(856	)			—				(535	)			—				—				—				—
Total Adjustments		$	5,354			$	(875	)		$	(99	)		$	(8,816	)		$	5,158			$	—			$	(58	)		$	(29,525	)
Adjusted		$	114,046			$	32,219			$	5,136			$	25,033			$	129,269			$	48,404			$	7,492			$	30,597
% of Revenue			74.6	%			21.1	%			3.4	%			16.4	%			75.1	%			28.1	%			4.4	%			17.8	%
Currency Adjustment			334				40				2				19				N/A				N/A				N/A				N/A
Constant Currency		$	109,026			$	33,134			$	5,237			$	33,868				N/A				N/A				N/A				N/A
% of Revenue			71.1	%			21.6	%			3.4	%			22.1	%			N/A				N/A				N/A				N/A
Adjusted Constant Currency		$	114,380			$	32,259			$	5,138			$	25,052				N/A				N/A				N/A				N/A
% of Revenue			74.6	%			21.0	%			3.4	%			16.3	%			N/A				N/A				N/A				N/A

Note: Totals may not sum due to rounding.

⁽¹⁾  Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization.

⁽²⁾  Restructuring charges, from previously disclosed restructuring plans, consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments.

⁽³⁾  Expenses in connection with the management of certain executive matters.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

		Successor																																Predecessor
		Nine Months Ended September 30, 2026																Period from June 25, 2025 through September 30, 2025																Period from December 29, 2024 through June 24, 2025
		Gross Profit				Marketing Expenses				Product Development Expenses				Selling, General, and Administrative Expenses				Gross Profit				Marketing Expenses				Product Development Expenses				Selling, General, and Administrative Expenses				Gross Profit				Marketing Expenses				Product Development Expenses				Selling, General, and Administrative Expenses
GAAP		$	341,507			$	173,903			$	19,768			$	132,286			$	133,020			$	51,188			$	8,236			$	62,975			$	263,384			$	110,871			$	25,281			$	78,480
% of Revenue			70.6	%			36.0	%			4.1	%			27.4	%			72.2	%			27.8	%			4.5	%			34.2	%			72.4	%			30.5	%			7.0	%			21.6	%
Adjustments:
Transaction Costs (1)		$	—			$	—			$	—			$	—			$	—			$	—			$	—			$	(9,308	)		$	—			$	—			$	—			$	(20,873	)
Depreciation and Amortization Expenses			15,865				—				—				(48,986	)			5,465				—				(62	)			(21,647	)			8,650				—				(115	)			(5,440	)
Restructuring Charges (2)			(65	)			—				—				(377	)			23				—				—				(99	)			(2,455	)			—				—				(2,333	)
Share-based Compensation Expense			1				(321	)			(317	)			(1,484	)			—				—				—				—				—				—				—				(4,032	)
Executive Related Costs (3)			—				(856	)			—				(5,897	)			—				—				—				—				—				—				—				—
Total Adjustments		$	15,801			$	(1,176	)		$	(317	)		$	(56,745	)		$	5,488			$	—			$	(62	)		$	(31,054	)		$	6,195			$	—			$	(115	)		$	(32,677	)
Adjusted		$	357,308			$	172,727			$	19,451			$	75,541			$	138,508			$	51,188			$	8,174			$	31,921			$	269,579			$	110,871			$	25,166			$	45,803
% of Revenue			73.9	%			35.7	%			4.0	%			15.6	%			75.2	%			27.8	%			4.4	%			17.3	%			74.1	%			30.5	%			6.9	%			12.6	%
Currency Adjustment			(4,054	)			(988	)			(8	)			(294	)			N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
Constant Currency		$	337,453			$	172,915			$	19,760			$	131,992				N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
% of Revenue			70.5	%			36.1	%			4.1	%			27.6	%			N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
Adjusted Constant Currency		$	353,254			$	171,739			$	19,443			$	75,248				N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
% of Revenue			73.8	%			35.9	%			4.1	%			15.7	%			N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A

Note: Totals may not sum due to rounding.

⁽¹⁾  Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization.

⁽²⁾  Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.

⁽³⁾  Expenses in connection with the management of certain executive matters.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

		Successor																Predecessor
		Three Months Ended September 30, 2026				Nine Months Ended September 30, 2026				Three Months Ended September 30, 2025				Period from June 25, 2025 through September 30, 2025				Period from December 29, 2024 through June 24, 2025
Net Income (Loss)		$	15,108			$	(22,818	)		$	(57,516	)		$	(56,262	)		$	1,118,103
Net Income (Loss) Margin			9.9	%			(4.7	%)			(33.4	%)			(30.5	%)			307.5	%
Interest			10,861				33,925				12,052				12,975				38,664
Taxes			10,692				10,360				53,157				52,634				1,669
Depreciation and Amortization Expenses			13,050				64,851				25,493				27,174				14,201
Share-based Compensation Expense			705				2,123				—				—				4,032
EBITDA		$	50,416			$	88,441			$	33,186			$	36,521			$	1,176,669
EBITDA Margin			33.0	%			18.3	%			19.3	%			19.8	%			323.6	%
Franchise Rights Acquired Impairments (1)			—				—				—				—				27,549
Reorganization Items, net (2)			—				—				—				—				(1,143,918	)
Gain on Extinguishment of Debt (3)			—				(4,612	)			—				—				—
Transaction Costs (4)			—				—				9,126				9,308				20,873
Restructuring Charges (5)			—				313				122				122				(122	)
Executive Related Costs (6)			1,391				6,752				—				—				—
Other (7)			(147	)			(1,305	)			342				1,274				6,685
Adjusted EBITDA		$	51,660			$	89,589			$	42,776			$	47,225			$	87,736
Adjusted EBITDA Margin			33.8	%			18.5	%			24.9	%			25.6	%			24.1	%

Note: Totals may not sum due to rounding.

⁽¹⁾  The Company’s franchise rights acquired impairment charge related to its United States unit of account.

⁽²⁾  The net reorganization gain related to the Company’s emergence from its Chapter 11 financial reorganization and primarily consisted of the gain on settlement of liabilities subject to compromise and the impacts of fresh start valuation adjustments.

⁽³⁾  Gain on extinguishment of debt consists of the Company’s voluntary prepayment in May 2026 of a portion of its New Term Loan Facility at 68.5% of par.

⁽⁴⁾  Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization.

⁽⁵⁾  Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.

⁽⁶⁾  Expenses in connection with the management of certain executive matters.

⁽⁷⁾  Primarily consists of the impact of foreign currency on intercompany transactions.

Exhibit 99.2 ORMADE F t 1 mos# NAME: ted ustr yelrebmik progress: MEMBERS m ian 2026 grors Psot LhgieW * sbl 23- k / eewsweo Ng tindrocca program: krpaSdnarB stniop rreettdel3oQLh6e20r2ahS von56202

etadpU ssenisuB eQ3 2026 rflos grtcewt ihn or uhgihre-lavue offsginre %84 werg euneveR noitpircsbuS lacinilC elihw ,raey-revo-raey %11 nwod ,noillim 9.251$ saw euneveR 3Q :euneveR . noillim 0.83$ ot raey-revo-raey evitucesnoc htruof a gnikram ,raey-revo-raey %61 pu ,dnasuoht 645 dehcaer srebircsbuS doireP fo dnE +eroC 3Q :+eroC . sraey 02 ni deveihca ton evah ew enotselim a ,htworg rebircsbus laitneuqes fo retrauq hcaer ot seunitnoc +deM .raey-revo-raey %04 pu ,dnasuoht 471 erew srebircsbuS doireP fo dnE lacinilC 3Q :lacinilC ni srebmem wen hcus morf gnimoc spu-ngis +deM fo %06 yletamixorppa htiw ,srehctaW thgieW ot wen era ohw elpoep . 5202 3Q ni %05 yletamixorppa susrev ,6202 3Q erofeb retrauq eht ni dneps rewol gnitcefler ,euneveR fo %6.12 ro ,noillim 1.33$ saw esnepxe gnitekram 3Q :gnitekraM . oiloftrop ruo ssorca dneps fo noitacolla deunitnoc htiw nosaes kaep 7202 hcaorppa ew i eerht tsrfi eht fo tsehgih eht htob ,%6.47 saw nigraM ssorG detsujdA dna %1.17 saw nigraM ssorG 3Q :nigraM ssorG . 6202 fo sretrauq i 7.15$ saw ADTIBE detsujdA dna ,nigraM emocnI teN %9.9 a gnitneserper ,noillim 1.51$ saw emocnI teN 3Q :ytilibatfiorP i . nigraM ADTIBE detsujdA %8.33 a gnitneserper ,noillim ta noillim 5.101$ morf pu ,3Q fo dne eht ta noillim 4.621$ erew stnelaviuqE hsaC dna hsaC :stnelaviuqE hsaC dna hsaC . 6202 2Q fo dne eht 526$ ot segnar ecnadiug 6202 raey lluf dedivorp ylsuoiverp ruo gniworran era eW :ecnadiuG 6202 YF gniworraN ii . ADTIBE detsujdA fo noillim 511$ ot noillim 011$ dna euneveR fo noillim 036$ ot noillim srotacide IncnamrofreP AH% CNGE noillie mloht wsereae nho td tedunoe runeveR6202 3Q 5202 3Q 1%)(1 euneveRM351$2M7$1 22%)( laroivaheB4M1$145M$1 $38M$26M laciinlC48% 2.3M3.0M(23%) srebircsbd Suoiref Pd oEn laroivaheB1M2.2.9M26%)( laciinlC4K714K210%4 r ee Puneven Roitiprcsby SulhtnoM 711.$228.5$1 1%4 RPU)r (Aebircsbe SugarevA scitrel MaicnainF 3Q2 0263Q2 052 ingras MsoGr1%71.1%2.7 i ingras Msod GretsujdA4.6%71%75. s)soe (Lmoct IneN1M$15.)M.57$(5 ingras) Msoe (Lmoct IneN9.9%%)33.4( i ADTIBd EetsujdA7M$51.$42.8M i ingraA MDTIBd EetsujdA33.8%4.9%2 . rebircsbe Sugarevr Aee Puneven Roitiprcsby Sulhtnod Mns arebircsbd Suoiref Pd oe, Enunever Ros fnoitifiner dos” frotcaide Incnamrofred Pns anoitifin Se “Dee s. eurseal maicnaP fine GAAlbarpamot csoe mho ts ttnetmsujdn al oiater dehtr furos” feurseal MaicnainP Fn-GAAof Ns oeurseaP Mo GAAn toitailicnoceSe “Re l aicnad finne acnerurcce ohg tintscaeroy fletaurccf ay otulciffit dneree ihnhf te osucaet broffe elbanoseart unuohtid wedivore pt bonne camoct ineo nk tootluA oDTIBd Eetsujdr Aeal yg fulinkood-lrawroe fhf tn ooitailicnoceA r s sesso ae tlbas uny inpamoe Chs, tnoseae rme sahr tod. Fetcidery plbanoseae rt bonlonr ca, otrnos cy'npamoe Chf tt oue ord, aerurcct oet yoe nvat hahn toitailicnoceh rcur soy frsaseces nmetg iintsujds auoirae vhf tt ocpaim s.tulsel raicnaP fine GAAurts futn it ocpal imairetae a mvad huloh ccihn, woitamrofe inlblaiavae unhf te ocncafiignie slbbaore pht 1

ONE STRATEGYOEN PLATFORM DAANITPG O TTE HKARMETSUPPORT AT EVERY STAGE al toT,d etbbefore s.v t aemergence Q2 2025 fot bed 1.6B$ d evomer TSERE 56M4$ morfe ht teseR ehte cnlabat eehs dnat esu rof B511$. ecnalabteehs cigetatrss.rlalip erofeB tAecnegreme Revenue per subscriber by quarter Q3 2025 71.1$2 .902$0 952$.0 2026 y lhtnom 789.$1 37.8$1 2.85$1 428.$1 2052 e unever ETIINTFREEDAF rep, rebircsbus4202 etaitnereffDi eulav-rehgih sreito t tropups 2.85$14.471$ .307$1 pu %9 morf 3Q42' .0071$.9961$ s rebmem tay revee.gats Q12QQ3Q4 Gross margin · GAAP j . ad Q4 2025 46.7% .447% ; nigram ssorg 736.%.376% d etsujda i nigram ssorg TREASMLNEI d rocer raen 171.% S einlmeatr snoitarepo dnat cetorps ingram %4.47 ta shgih07.5% 730.% 1%.0710.7% s a eulav-rehgihr eit siphsrebmemorgw. Q4'25Q1 '262 Q'263 Q'26 End of period Clinical subscribers Q1 2026 719K Clinl aci sucsbrbier 310K 421K SCALE gorwth C deuintnot netmseving indleiy elcasin i n aqretrau 1%+5 Mde+ g.inreffo 3 Q2025 Q420251Q 2026 Q2 2026 term anol paydown Q2 2026 mret naol, deriter 4.1M$4 86M3$. M 0.564$ NERTSGTHNE otM 6.324$ S nehtgnetre ht ecnlabateehs: etareneg 4M1.4$gnidnatstuo h sca dna ypaodwn t.bed C hsaytlauo tDbedeirter Core+ hsare of al totsubscribers Q3 2026 42% fo ruos rebmem won e soohc 22% e ulav-rehgih 20% FOCUS +eroC 42% F suco tnetmsevin nowt ah stes su trpaa: naumht.roppus 1 Q20262 Q2026 3Q2026 Q3 NNCOEC STTHE CPEIES W tah ew nrael sepahs erehw ew.tsevni . rebircsbuSe garev rAe PeuneveR noitiprcsbSuy lhtno dMna srebircsbuSd oire Pf doenE ,uneverR os fnoitifine dro sf”rotcaidI encnamrofreP dns anoitifin S e“D ee .s eurseam laicnafiP nG AAelbarpamot csoem ho tst tnetmsujd naol iate drehtfr uro” sferusealM aicnainF PnAAG-of N oseruseaMP G AAo ntoitailicnoceS“ eRe 2

oT ruO deulsarVedloherahS thgieWs rehctaWs aw tliub no an oitcivnoct ahts ah ylnon worge rom:t navelerg ihnceard nag iinnatsust hgiew s sols eiruqere htt hgirn oitainbmoc fot ,netmeatr ,ecnadigud nat. roppus roFe romn ahtx iss ,edcaed uro dekc-ebacneics ,smargorp, sehcoac dnay tinummoce vahd eplehs rebmemh ceari rehtt hgiew ssol. sloag 1 -PGLs noitcaideme ra gimnrofsnatrt hgiewt .nemeganamg intargetIne sehtl caidems ecnavda htiwl aroivaheb t roppus dnan aumhn oitcennocs i tahws etaitnereffidt hgieWs rehctaW dnas plehs rebmemt uohguorhti reht t hgiew ssol. syenuroj e Scing imnocebt nediserP dna feiChe vitucexEr eciffOn or ebotOc1 , I evah edam ti ay tiroirp ot dneps eimt g innetsilo t uro ,srebmem ,sehcoac, snaiciinlcd eretsigers ,naititeid dna. seugealloci rehT secneirepxee crofiner g ihntemosl atnemadnfu tuobas ihts :seinsube rehts i on elginsh tpao t thgiew s,sold nae htt ropupse lpoep d eens eirav morf nosrepo t nosrepd nar evo. eimt I sawe tanutrof ot teeme noemost ae no fo uro spohskrowi n revDne ohws ahn eeba r ebmeme cins19, 66 dnae hs derahs reh lanosrep yrots fog inteemn eaJ,h ctediN eht r ednuoff o thgieW. srehctaWr eHy rotsd edimner em fo yhw ew odt ahwe w od yreve, yadd nae ht elbidercin dnae vitisopt cpaim ewe vahn o os ynam ’selpoep .sevil eWi namerd ettimmoc otg inginrbl caiinlc erca rehtegot htiw laroivahebt, roppusg, ihncoacd na. ytinummoc eW lliwe be tarebiled dna deinilpcsidt uobae rehw ews ucofd nat ,sevin ginsur ebmem, kcbadeef tnemegagne at, ad dna elbaruseams tulser ot edigu ruos. noisiced eW erag inningebo te esg ingaurocnee cnedive fo woh srebmeme ra gindnopser ot ruo eulav-rehgiht cudorp s. ginreffoe hTr ebmun fo +eroCs rebmemg inkat 1-PLG snoitcaidem sahy lreand eilptr revo ehtt spa ,reay elihw %04 erom+ eroCs rebmem detipacitrpai n luatirvs ecneirepxen aht ar eay. ogae sehTs tnempolevede crofiner eht ecnaveler fo giinnbmoc ehtl caidems ecnavdag imnrofsnatrt hgiewt nemeganam htiw eht yrsasecen t, roppus laroivaheb e,cnadigu g,ihncoacd na ytinummoc tahte vah gnold efinedt hgieW.s rehctaWr ehtehW s rebmem eviecer noitcaidemd ebircserp ybt hgieWs rehctaW ciinlCr or ehtona, redivorp ew erad esucof no gindivorpe htt roppust ahts teemir eht ,sdeenr everehwy ehte ran oi reht. yenruoj e rehWu ro sseinsuBs dnatS noititepmoCi n ehts sol-thgiew yrogetca seuintnoc ot eb ,detbaaung incrofinere ht ecnatropim fog inthgilhgih ehtn oitaitnereffidf or uos ginreffoh cihwe divorpt repxe e,cnadigu dezilanosrept ,roppus dna .ytiunmmoct ahT si erehw ew era gintatrnecnocr uo: stroffe :+eroC +,eroCu ro eulav-rehgih laroivaheBg, inreffo wegr srebircsbus rofe hth truof evitucesnoc ,retrquaa enotselim ew evaht ond eveihcai n 20 .sreay gnomA srebmemg indagrpum orfe roC ot ,+eroC ylhguore no i n evfis awg inkata 1-PLGi nQ 32026 , derpamoc htiwy letaimxorppa enoin y tnewti n Q3202 .5 sA noitpoda fo wen thgiews sols noitcaidem, swogr ew eveilebg invlove urom roftlap ot tropupss rebmem r evewohy ehte soohc ot hcoarppai rehtt hgiew ssol yenruoj snoitisops ur of mreg-tnol s.seccus :l aciinlCd +eM sdliubn oe htl aroivahebn oitadunof fo +eroCd na sdda ginogno ercam orfs naiciinlcd einatr ot troppuse lpoeph tiw. ytisebos ihTn oitargetins ehsiugintsid urog inreffom orf’ srehtos ecivresd etiimlo ta n oitiprcserp .enola+ deMs euintnoc oth ceare lpoepo hwe raw en ot thgieW,s rehctaWh tiw yletaimxorppa 60% f o+ deMs ugpn-is gimnoc morf hcusw en srebmemi n3 Q2026 , susrev yletaimxorppa% 05in 3 Q 220. 5 g:intekraMI n ,rebmetSpe ewd ehcunlae hTh gieWI ,na y lkeewt scadopd etsohy b atihSma, yayhdpaohkuM r uo deaHf o tnetnoCd nat, cpaIm ginrolpxe sso-lthgiew ,syenurojs senllew sdnetr dna1 -PLGamg .its ehT h cunald etcattra lanoitan ,egarevoc gindulcin a weNk roYs eimT.e lfiorp eWe uintnoco te tarbilcaerd na y fisrevidu ro gintekramh coarppa ot dnpaxee hth cear fo ruot cudorps ginreffoh guorhtd etegratt netnoc dna rotearcs ,noitaroblaloc elihwg inrolpxes eitiuntroppoo tw adr no ehts ihpsnoitaler uro sehcoace vah detavitulcihn tiwi reht.seitinummoc 3

tahW ruo sginreffOe arSh ,eroCr uol atigid laroivaheB g,inreffos edivorpd ekc-beacneicst nemegana-mthgiews lootd nal aroivaheb e.cnadiug +,eroCr uo eulav-rehgihl aroivaheBg, inreffo sdda,g ihncoac, spohskrowl autirv s,ecneirepxed na d ezilaicepss ,margorp gindulcin1 -PLG,s seccuSh cihws tropupss rebmemg inkat1 -PGL snoitcaidemn eve nehwd ebircserp yb sredivorpe distuo fo thgieW srehctaW c.iinlC d,+eMu ro lcaiinlC ,ginreffos dliubn o siht l aroivaheb noitadnuof htiwg inognoe rca morfs naiciinlcd einatr ot tropupse lpoeph tiw ,ytisebog indulcin sseccao t noitiprcserp tnetmeatr rofe lbigile,s rebmemd etagretinh tiwl aroivahebd nay tiunmmoct. roppus rehtehW srebmemi natbo1 -PGLs noitiprcserp hguorht thgieWs rehctaWc iinlCr o rehtonae rcahtleah, redivorp u ro smagrorp tcennoc meht htiwe ht laroivaheb ,ecnadigu lcaiinlc ,esitrepxe dna namuh tropups yeht deen tuohguorhti reht thgiew ssol.syenruoj MEMBER OUTCOMES 2%9%0329% MORE WEIGHT LOST WITH REGULAR LESS LIKELY TO DISCONTINUE FEWER CALORIES FROM ULTRA- ENGAGEMENT WITH GLP-1 SUCCESSTHEIR TREATMENT PLANPROCESSED FOODS thgieW srehctaW de srebmemt hgieWs rehctaWs rebmem ohwt emh tiwa deretsige decuderir ehts eirolca morfatrlu naititDeie rew ssely lekilo t dessecorps doof yb, a e uintnocsidir ehtt netmeatrn lap elbignatr ekram fo eht lear ih ntiwe ht tsfir skeewd erpamocl aroivahebs tfihsm orfr uo ote soht ohwd idt on teem htiw nah.coarppa .D g inrevDile eulav ytlnetsisnocs neam ginsoohce rehw ot .sucof eW eveilebe lbainatsush twogr lliwe mocm orf g insucofn ot ahws rettamt somo t uro srebmem dnao t ehts: seinsub O ru srebmeme moct .sfirn ehWy eht,d eeccus ehte cnamrofrep fo ehts seinsubl liw. wollof eWl liws ucofn o tahws tes su :trpaan aumht ,roppus ,ytinummoc dna ehte sitrepxef o uro ,sehcoac s naiciinlcd nad eretsigers. naititeid e W lliw eb atadn ,evidr etaulaves emoctuo, ylevitcejbod na elcas lfusseccuss. evitaitiin eW lliwe b deinilpcsidh tiwy rever allod ew ,dnepsr ehtehws ihts ii n g,intekram tcudorpt nempolevedr o , ygolonhcetd nat ceird ti erehw ewe veilebs ihtt netmsevin lliwe tearc ehtt som eulav rofr uo srebmemd na r uos. redloherahs erehT si leark row. deaha I leefd oogt uoba ehtn oitadnuofe re’wg indliub n,oup dna I ma nevee romd eticxe t uobae ht erutuf fo siht. sseinsub I mau fletagr ot uro srebmemr ofi rehtt ,sutr ot uros, ehcoacs ,naiciinlc deretsigers ,naititeidd nas egueallocr ofi reht tnetmimmoc ot uro s,rebmem dna ot ,uoyu ro ,sredloherahsr of r uoyt.ropups nehpetS, eyB t nediserPd naf eiChe vitucexEreciffO 4 Se es” ec“Sruoih ntiws ,ec“Suro snoitifinDe dna laicnainFs ”liatDen oitces rofr ehturfl iatedn o.setotnoof

hTeL eerv slefouS opptr sseccA1 -P|D G+ LEM t.4ropupsl caiinl dcnea, lbigil efin, oitcaide m1-PGLd evorpp-AaDoF t ssecct aGe eutraCOng+RE| Si t.ropupts repxe dna sehcao cnamu hginurtea f— magrorp eurtangi rush otiwt hgiewe soL cisaCOR |BE e dne alpimts Geffd n athgiee wsool stloo tevitce OCERCO+RED+EM .stibah htleadh liub FOOD AND NUTRITION m5agrorp® stinoP dednemmocer-rotco#d1 seipcerd nae cnadiu ngoititruN sorca mdina netorg pinkcarT COACHING & COMMUNITY sesslac ssetn fieviLdetiimlUndetiimlUn n)osrei d-pnn laautirs(v pohskroWl6ai ktreew-2detiimlnUdetiimlUn CONDITIONS AND LIFE STAGES margorPs secc 1Su-PGL esupaone omtd erolia ttropSup CLINICAL SUPPORT 4/72 Cn aiciinlCmeaTe ra ginkcae trDso R eedis dnas redinmerl lfieffginkca ttrce Itropups ecnarusn 5 s.etotnoofn lo iaterd ehtrruf o fnoitcess ”liat lDaeicnain dFna snoitifins ,Deecih nS“uroti”s wecSSe “rueo

ecnamrofreP laicnaniF 6202 3Q kooltuO 6202 dna 6

UPRA dna srebircsbuS retr qaeuvitucesnoc hturor af of wesr grebircsb+euS roC i rePe uneveRn oitiprcsb ySulhtnoMRUP Alaciinl Cdnla aroivaheB i )PRUr (Aebircsbeu SgarevA lcaiinlClaroivaheB 32$97. 711.$2 $.0920 $078.2 28$65. 052.$955.76$$85.26 12.71$ 378.$1 4.071$ 258.$1 .862$1 %41+ Y/Y 39.6$1 6.321$ deuintnoc ehtg intcefle, r711.$2 saw )RPUr( Aebircsbe SugarevA rePe uneve nRoitiprcsbSu ylhtno Q3M e+roih nC twogs r allew s s,aseinsu lbaroivaheur Bm oorsf seinsulb caiinl Cur oot tfih xsir mebircsbus .sseinsu blaroivahe uBriho nti wsrebircsbus i srebircsbSdu oirefP donE)k ( wegr srebircsbSul caiinlCd oire fP doE nQ3%04rea y-revo-7o 1rt eay4 laroivaheBd oireP fo ddn. Ensauoht 2d einlce sdrebircsbuS6%reay -revo-.n oillim 1o2. tr eayW+ ero dCeuintno,e cinlced o steuintnoc eroe Clih f 1 hotwogr rebircsbus%6reay -revo-o rteay654 retearg revile od ytgetatrs ru foon oitadilav sedivorpd nsauoht ilanosre fp solever lehgi hhguorht eularv ebmemz.ytiunmmocd n g,aithncoac, ropupds e ii srebircsb SluaroivaheBd oirePf od nE(k) srebircsbSul aciinl Cdoiref Pod En() k 6%)2( /YY%04+ /YY 22,86791719 316,2 471 3642, 1922, 221,2 130 421 .rebircsbu eSgarev rAeeP unevenR oitiprcsbyu SlhtnodM nsa rebircsbuSd oirefP d ofnE sonoitifine dro” fsrotcaidIe ncnamrofre Pdn sanoitifinS“e Dee 7

nigraM ssorG dna euneveR raey-rev-orae p%euy8 4uneve nRoitiprcsblS uaciinlC d n naoillim0 .83$ o rteay-revo-rea y%8w 4eer guneven RoitiprcsbSl ucaiinlnC. oillim9 2.51$ sawe uneveQ3 R s einlcee, duneve nRoitiprcsbul Saroivahieh nBti m i%15Q 5.3 W202norfp u e,uneveR lato tf5od % 2etneserper g.inreffeo ro rCu idn oetatrnecnoe co bt euintnoc )m$(e uneveR 271 861 361261 153 921 121 451 411Y/ Y)%22( 314 04 3983 Y/84+ %Y 2672 lcaiinlClaroivaheBeuneveR rehte dulcsi nlato i ingraMs so Gdretsujd Adna 1%s 7a.1iwn gras MsoQr3G odt erpamoic ngraMs soi ernG searce inh4T.%6. 7 sa w t nemngild aeuintnod cn astso cdexrfi ewolo tsevitaitiy incneiciffle anoitarepg oinognoy b nevids ra w6202 2Q .sesseinsufb soein luro ssorc aseumlovr ebircsbus urh otiw ingraMs soGr euneveR fo % 1%75. 4%6.7 %4.47 37%6.7.36% %12.7 %17.1 5.%07 0%73. %1.07 i ingrasM soPrG AAGingraM ssod rGetsujdA s.eursea lmaicnaPfi nAAG elbarpamoct so emhto t stnetmsujdna lo iate rdehtfur ro”s feurseaMl aicnainP FAAGn-ofN s oeursea MP GoAAt noitailicnoceSR e“e 8

sesnepxE gnitarepO dennal ps, araey ehf t roetrgqa uintekratm sewoL tnetmsevin nosea-skeap detavele ginwollo Fe.uneve Rf%1. 6or2 n ,ooilli 1m.33$ ere wsesnepxe gintekra MQ3 . sginreff ofoo iloftropur ossorca dneps gintekra emtarbilcaeo rtd euintnoce lcaiiw, nli yC nlrualcitir, 1p Qna noitazitrom adna noitaicerpe drewo glintceflee ,runeveRf o %1 2.2ro n,oillim 8.33$ ere wsesnepxe A&GQ 3S i &AGS detsujdA .einilpcsid esnepxe deuintno cdnae. unevef Ro %.64 1r on,oillis25 m0$ .a w seicneiciff leanoitarep ogintceflee, runeve fRo %. 43rn, ooilli5.m2$ e res wesnepxte nempolevDt ecudor3Q P l atigi ddnm aroftla gpinogno htiw noitcennod i ncezilatipc satsotc nempoleve fdon oitroporr pehgi ahd na .stnemecnahne ecneirepxe i sesnepxgE intareOpsesnepx gEintareOp detsujdA euneve fRo% euneve fR o% %8.4 %4.5 7%.4 6%.28 %4.4 .4%08%4.1 %.54 %34.2 %6.71 %.44 .%93 %394.%.43 31%.0 %3.4 85.1% 8.%71 1%2.2 %.461 2.%551%5.5 %.024.%024 29%.5 %29.4 %1.82%18.2 %.162 %11.2 Q 32520Q4 2520Q1 206262220 Q3Q 2062Q5 2023Q5 2024Q1 206262220 Q3Q 2620 gintekraMdinmA l &are G,gnienlSletnempolevD tecudorPgintekraMdinmA &lareG, gnienlSletnempolevD tecudorP .seruseam laicnaPfi nA AGelbarpamotc some h tos ttnetmsujd an oliated rehtr fruosf” erusealM aicnainF PAnA-Go Nfso erusea PMGAA on toitailicnoceSe “Re 9

ytilibatfiorP i ADTIB dEetsujdAd n anoilli m1$1 5.fo emoc tIneN3eQ vitisoPf o ytilibatfiorg pnotrs tceflenr oilli7m .1$5 noitaicerpef dn ooilli.13 m0$ dedulch incihi n,)wgraeM moct Inen 9% N9.(oilli m1$.s51 a wemocIt ne N620Q 32 i ADTIBE detsujdeA. snepxxe a fton oilli m70.$d 1ne asnepxt eseretfi nn ooillim 9.0,1n$ oitazitrom adnas aw i ingra AMDTIB Edetsujd 3A.%83( noilli7m .$51 dnae cnamrofre gpintarepgo notrds euintnog cintcefler), .sretrarq uoirm porfr evo ginyrrct anemeganae msnepx deeinilpcsid ingrasM) so e(LmocIt neN dn($am )s )soe (Lmoct IneN 15 41 )(6 )25( )85( 3Q 6022 )%33(%)4(3)1%(%9%01 i ingraM ADTIB Edetsujd AdnAa)m$( DTIBE detsujdA 25 34 04 81 )2( Q6 2023 %52%11(1%)%42%43 .seurseam laicnaP fineGAA lbarpamo tcso emht ots tnetmsujdan lo iated reht rrfuo” sfeursea Mlaicnain FP-nAAGofN s oeurseaM P GoAAtn oitailicnoceSR e“e 01

teehS ecnalaB dna wolF hsaC 6202 2 Qmor nfoilli$25mp u e cnalabh saC $3s .23a wsnoitareOp mor fwolFh sa Q 2.36f20Cod ne eht tan oilli m426.1$ erews tnelaviqu hEsadC n hasaC hse caho T.na mlreru to ecivreo stt serety inlretrqa fuon oillim 4.1 s$1edulc hincih ,wretrauqe h ni tnoillim .retrauq ehin t noilli. 0mf$ 7o seurtidnepxe dezilatipcs atcefleor slf3 Q ao dnee htt ae cnlaba )m$h (saC)$m(s noitarepO morhf saC 710 23 106 24 +s $25vm.2 Q 621 121 101 (3)(3) (43) 3Q 202663 2Q02 ginwollo fteeh escnala bur doemrofsna tyrllatnemadneuf va ehW n:oitazinagroel RaicnainF2 5202 uQ ro n aoL mreTy tirutaMe ta RtseretInp eewSh saC r ev yotb bed lato tdecudeR2400 3,e 2uJn sisR+ 8 0 b6aSOFs secxe ro sftnemypaerlp aunnA 2 niQ noilli .b$6 m1orf 0%7 ott cejbu s,stinopd esn,b aoill0i0 m$e1 vobah sca gindnatstuh oti2w ,502snoitidnoinc atrecf os yard adnel 0ca1t sael hn to fo s anoilli4m 24$f ~o ecnalbaretrtqau se firht Q30226 11

kooltuO 6202 – noillim52 f$ 6oe uneve tRcepxew on e .sWegnar ecnadi20d 6u2g edivorp ylsuoiverp rug oinworran er eaW i ADTIB EdetsujdAd nn) aoilli563 n $ m–oilli2m 0$y6 lsuoiver p(noilli$m 630 noilli m51–$ 1 noillim 01 f$1 o . n)oilli15 m1$ – noilli0 5my$ 1lsuoiver(p e uneveR .s rebircsbu se+ro hi Cntwog rreay-rev-orea tycepx eo teuintnoce la, wroivahieh nBtiW fo%6 1 morfpu ,e uneve Rlato2 t6f02 %y5 o 2letaimxorppa eb ote uneve Rnoitiprcsb Slucaiinl tCcepxw eo neW . euneve Rlatot5 202 in gar sMsorG ii ingraMs sordG etsujdAt hgil sa tcepxeo te uintnoce We o btt t icepxwe od nn20,s 2a5usreie i20 vn62 nlce d 2)%0.. 7e voba ylsuoiverp( %0.47y letaimxorppa n oitareG hnseaC – noilli45m y$ letaimxorppag indulc i2 2,06fn roediname rehh tguorh thsce atareneo gt tcepxeo te uintnoe cW s exaht scs, aretr 22u6qr a0oirph tiwt netsisnosc erutidnepxel atipcy alretr,q austso tcseret finno oilli0m $5 s.tnemypg aintekra fm goiimn tdnan ,oilli0m 1$ dna noilli$nm 5eewteb daehAg inkooL sseinsue bht fyo ticpn caaoitareneh gsdc an aytilibatfiore phe ttatrsnomes dtulser retru-dqaihrO rut h. twor grebircsbus laitneque sfro etrua eqvitucesnoc htruofs tgi inrevilee +dro Chtiw s,ginreffour os etaitnereffidt aht tropups namueh htf eo ulav ehgt intatrsnome dns oinames rucourfO ruos sorc daerahss eitilibpc eaah tng oindliu dbn s,atnetmsevi ginntekrar umof o hcea erh gtinvorpim n oitisopl liws eitiroir epsehts sorcan oitucex tenetsisnoce veileeb W s.ginreffo+d e Mdn+e, aro,e CroC .htwo mgrre-gtno lelbatfiorp ,elbainatsu sro fsrehcta WthgieW yletaurcc af yotulciffit dnereei hnhf t eosucaetb roff eelbanoseartnu uohtid wedivor pet bonn ecamoc itneo nkt ooltuAo DTIBd Eetsujd rAea lygluf inkoo-ldrawrofe hft o noitailicnoceA r ebt onlonc ra, otrno sc'ynpamoCe hft ot u oerd ,aerruccto e tyo nevah tah ntoitailicnocer hcurs o yfrsasecesn meti gintsujd sauoirav eht f tocpali maicnadfi nn eacnerrucceo h gtintscaerof PeG AArut sfut nito cpa ilmaireta m aevahd luoh ccih ,wnoitamrofi enlblaiavan euhf t oecncafiigni eslbbaorep h stsesso ate lbau ns iynpamoCe h ,tsnosear emes ahrt od. Fetcider pylbanosear . stulser laicnafin s.eurseam laicnaPfi nAAG elbarpamoct som eht ots tnetmsujdn aol iated rehtfrr uos”f eurseaMl aicnainFP nAG-AofN os eurseaM PoGAA t noitailicnoceSe “Re21

drihT retr aeucQnerefnoC llaC dna tsacbeW ehTy npamoC sah deuldehcs a ecnerefnocl lca yadot ta8: 03a ..mE T ots sucside h T.stulsert scabew fo eht ecnerefnoc llcal liw eb elbaliavan oe hts ’ynpamoCe taroproc ,etisbew ,moc.wwe.taroproc reduns tnevEd na .s noitatneserP Ay alper fo eht tscabewl liwe b elbaliava no siht etisr of ta tseal9 0 s.yad tuobA thgie sWrehctaW t hgieWs rehctaW si ehtl baogl redealin d ekceb-acneicst hgiewt, nemeganamg inreffon a detargetin tropups m etsyst liub rofe ht1 -PLGa re tahts einbmocc fiitneics e,sitrepxe ,noitcaideme gd-geinttuc, ygolonhcetd na n aumh n.oitcennoc htiWe romn aht 60s reay fo ,ecneirepxet hgieWs rehctaW si eht tsom deidutsl aicremmoc t hgiewt nemeganamm argorpi n eht ,dlrowd ereviledh guorht stio .N1 . SU.d ednemmoce-rrotcods sol-thgiew 5 m.agrorp stI, citsiloh dezilanosreph coarppa oslas edulcin des-.baSU. lcaiinlc snoitnevretin dnas secca ot 1 -PGL snoitcaidemn ehwy llcaiinlc e,tairporppad na a lbaogl krowtenf o sehcoacd nay tinummoct .roppus eScin196, 3 eht ynpamoCs ahd elh tiwe cneicso t revileds tis rebmeme htd ezilanosrept ropupsy ehtd een ot h ceard nain atsusi reht s.loag srebmeM ncas seccae sehts noitulos, ytlceird ro hguorht thgieW srehctaW rof s ’seinsuBu mtrcepsl-uflm roftalp rof ,sreyolpmeh tleah, snlapd na.s reypaI n a epcasdnlad edworch tiw y rotcidatrnoc e,civdag intlaosi s,ppad na llas-tfie-zis-enos ,noitulos thgieWs rehctaWs reffo an evorph tpa drawroft aht sid etoori n ,hcreaser dedunogri n yhtpame dnad engisedo t plehy rever ebmeml eef rettebi n i rehty dobd nae vila , regnol reihtleah .efilr oF erom,n oitamrofint isiv.moc.srehctawthgiew I“ evah tnereffid spohskroW“ era ,seitinummoc tub yleguht .natropmi eht tsom tnatropmi Y er'uo htiw elpoep eno si ym thgieW ohw evah ainuq eu srehctaW gnidnatsrednuof ytinummoc esuaceb tahw er'uoy gniog er'ew lla eht .emas .hguorht s'tI elbaplap Name:Name: er'eW lla gnikrow no eisseJMARAI taht enoyreve nac gnihtemos”.drah Progress:Progress: ”.etaler *** 85-bl 55-bl ,eisseJ— a,iraM— PROGRAM: WWrebmeMPROGRAM: WWrebmeM STNIOP+DEM 13 Se e“Ssecruo” ih ntiw“Ss, ecruoDefis noitin dnaF laicnainDsliate” noitces rofr ehturfl iated nos.etotnoof

dna snoitinfieD ,secruoS sliateD laicnaniF 41

secruoS * lt a .se oiclaaP. )thgiew ydofb o% 4.5( sbl 21f eogarevna t asom lagrorW peW ht fo lailt rcaiin sil n catinpacitr,p sahtnom6 t A CJ5N.. 22 0la A.i dtrellotrno dcezimodnar : Aytilq tauein dmo agrorp tnemeganatm hgie lwatigi fa dos senevitceffE ** , Jd Drat.A adr ebmem+ de WM fWoy dutls anoitavresb )tion anhgie ywdof b %o 4s9.(1b5 4.e4lgarevna o tsosl rebmems, htnom 2t 1 A tnetmeayt rtiseb ohtleahelem at orfe cnedived lrow-lear fs oisylan hatno-emvlewIT. MledraC , SykslodafN , Alcade ,MDG retsoF, R gYnoH 4. 022. ytis Os.enboitcaidem ytisebio-tn gainsur edivorp 1 dna +deM srehcta tWhgieW hguorh tllfien roitcaide1 m-Pt1 LGseat l daetseuqeor h swrebmemf 523,3 soisylanl aanreti nna no desa B 4 tseat la margorP sseccu S1-PLGe h tod in teggol ohw srebme,e mgareva2 O .n k5eetw at hgie wdn tahgiewg intratha sto dbetrope-rfles 2it n 5hgiey wdob% .207 1tso)9 l42np9=,( pea hot i dnt eggolr eve onhw srebmetmd n, ahgiew ydo2 0b. t%22sol) 76k=n( 3ee whcse ayad yam stulse lruadividd I.nefiire yvltnednepedn ineeb ton eva shemoctud oetrope-rlafS. ilelt rcaiinldc ellotrnod ,cezimodnar tao N.skeew . yrav 2 2 t 1si firerh tginurd srebmemd+ es MrehctatW hgie23,W 6 f4 5l02o2 irpoA t 4r202 ebmem Dcoeraf tad fos isylanal anret nina nod esa B t ae vaht o dnio dhsw rebmemn%3.9 . al ptnetmeairt erh dteuintnocsitd isiv1 tRDseat la dao hh swrebmeih . 5p.m6%srebme fmos keew rihpo srebmed+ mes MrehctaWt hgie Wginlecn csaneamn oituaintnocsi tdnetmear.T nla tpnetmeait rerhtd euintnocsidt isiv1t DR seal s. nlapt netmean troitcaide gmihnctiws 3 stinpacitrp daerpamoct aht) stluda6 7l(3= naitd rellotrnodc ezimodnarh tnlot a m.a0 6-5,22 seoicalaPf os isylanay radnoce asn o desa B la. c, Innoitanret WIny Wbd ednuF. enolsa einledil uganoititru dnradnatns evie gsoh otWt Wg inwollof 4 d eretsigeR roef lbigilet oe nras eiraicfiene bercaide .eMlbaliav sanoitpoy ph-asaC .ylppay ams elbitcude ddn eacnaursino, csypaoC . stisiv naititDei 5 s. tneitpo a tsmargorps solt hgiewd nemmocer ohw srotco0 d0f 5a ozivEnr enre yC ybevurs 3a 22n0 odesaB 6 i e nlbaliav areffihOp .srebmeMe ro Cea sahcrupu ony ehew err fo fspohskroW srehctat Whgied Wnettna uc ao,y skeewo w ttsurfi ro ryoF .ylno searag intipacitrpa 15

dna gnitnuoccA tratS hserF sdoireP rosseccuS dna rossecederP e h 0t 2,452,2 e Jnnus osecorp noitazinagroel raicna fisntim orf ecnegremes ’ynpamoe Ch htti nwoitcennoIc n ,9r 2ebme mDcoer dfoirer ”possecederPa“ sedulc32,i00 r52nebmet dSpeedn sehtnom eiyn s’nnpamoC ,yllanoitidd 02 2.A5,03 rebmetoS pe t5202 ,52 eJun mor dfoirer ”posseccd aSu“ n a,5402 ,2e 2nuJ o 4t220 laicnad finetadilosnoc eh, tyglindroccA.g intnuocc tarat shser fdeilppd an arofd efiiluaqy npamo eCht roir rpf oos s atnemetatls aicna dfinetadilosno echht tiw elbarpamoct one r,20 4a252 e Jrunetfas tnemetats ,13 rebmedD ceedne retrahu qturo5f2 ,02r,03 ebmetSd peedne retrdqu aihrt s’ynpamoe Ch Te.ta dtah tot d edne retruad qihrt dn2e0 62 ,03 anuJ dednre etrd uaqnoce 01h2,,6s23 craMd edner etr atuqs,25fi2 0r .doirerp osseccuS atneserpe lrl6 ra202 ,03 ebmetSpe 61

srotacidnI ecnamrofreP dna snoitinfieD ehth tiw sginreff otcudorp latigi’sy dnpamoCe h otts noitiprcsbusg indivorpo ts refes rseinsub ”laroivaheB“ s t fios noisrev deroliain tatre cdna spohskrow sy’npamo Ceh ot stsecca detiimln uoe tdagrupo t noitpo . margor epgnahc roivaheb y db edivor spginreffo tcudorl pcaiinlcsy’ npamoCe ht ot snoitiprcsbug sindivorop ts refes rseinsubl” aciinl“C s ginreffot cudorp noitiprcsbus latigi dsy’npamoCe ht hti dweinbmocs eitrd paihrtd nca iinl sCrehcta WthgieW e gnah rcoivaheb stif sonoisre vderoliaint atredc nsa pohskroyw’s npamoe Cho tts seccd aetiimln udna . magrorp e”, unevenR oitiprcsbl uSaroivahe ):“(aB fe otagegrgae hf t ostsisno ce”unevenR oitiprcsb u eO“- ur”Suneve“R e,” uneve RnoitiprcsbSu lcaiinl(db“ )Cn as;ginreffol aroivaheru Bo ro fsnoitiprcsbush ti wdetaicoss aseefe ht f ostsisnoe ”cuneve Rreht“O n,oitidds. I anginreffol caiinlru Cor o fsnoitiprcsbush ti wdetaicoss saee efht r ehtod nga ihnsilbu,s peitlayod rn asnla ptnetmimmo oct tcepseh rtiws eee fsihcnarfg ,insnecilm or efunever e. uneveR reht Odnae uneve RnoitiprcsbfS ueo tagegrgea hft o stsisnoce” uneveRe .“unever o h swrebircsbuls caiinl dCnsa rebircsbuls aroivaheB otr efesr” rebircsbsu-S“ ” rebircsbg SuimnocI“n citrem”s rebircsbg uSimnoc “eInh Ts.noitarepd oenwo-ynpamo is nCmagrorpl li gbinrurcee i rntipacitrpa yek eran oitneter dna tnetmiurtceR. ratsd oirep nevi a tgas noitarepod enwo-ynpamosi nC rebircsb sSutroper hcih wesb raebircsbus ehs i tnegnah crotinomo tcitresm ih tsezilitu tnemegana Mc.itrems ihr to sfrevidr . sdne tdrn ahtwoe gruneveu rrs otcpa iymtlceird -ynpamo si Cnrebircsbs Sutrope rcitrems ”rebircsbd uSoire fP od neE“h Ts -”rebircsbu dSoire fPdo n“E c. itre msih rtosf reviyd re ekr anoitneter dn tanetmiurceRd. n deoire npevig t as anoitarep doenwo u ros tcpay imltceirdh cihew s rbaebircsbu eshis nt egnahr cotinoo mtc itres mih stezilittu nemeganaM s. dnedt rn ahtwoe grunever e uneve Rnoitiprcsby uSlhtno“ eMh PT)”U R-”r A“(ebircsbS eugarev rAeP euneveR noitiprcsbyS ulhtno“M s ginreffor uor o fsnoitiprcsbu shtidw etaicosss aeef ylhtno emht strope critrem” rebircsbSue garev rAeP d n aylretr auhqto rbof euneve nRoitiprcsbyS ulhtnos. Messeinsubur or orf ebircsbeu Sgarev eAh ytb dedivid ehty bd edivi deuneven RoitiprcsbsS ua detalucl ceara sseinsue bvitcepse rhcre aosf doire peta-do-treay ylretr aruqo”r febircsbu eSgarev“Ae hdT .oiree ptad-ot-rea ry oylretrqeu avitcepseer hsi t nhtno fm roebumn s rebircsbu dSoireP f odd Ennas rebircsbug Simnoc Isntf ieo garev aeh tssi seinsu bevitcepseh rcer ao fsdoirep e vitcepser hc reaos fdoire epta-od-trea ryorf ”ebircsbSeu gareveA “h T.doirepy lretr eauqvitcepsere h rtof doireP f donsE tdi n raeay lcasfie h ftg oinninge ebht tas rebircsb gSuimnocI snt fieo garev eahs ti sseinsub o ctitre smih stezilittu nemeganad. Moirep etad-o-treaye vitcepser ehihtn ti dwnre etrhq uac reao sfrebircsbSu . sisrb aebircsbus re np aos dned trna htwor geuneverr edisnoc 71

gnikooL drawroF no etoN yranoituaC stnemetatS s af,3391 o tcA seitiure Sche ftoA 7n2 oit Sfce goinnea emhihtn ti” ws,tnemetatsg inkoo-ldrawros“ fedulc rinette rledloherahs sihT e htt uobas tnemetats yna ,raulcit ,girin pandulc, idnednem asaf9341 ,t oc eAgnahcxEs eitiureS cheft oE1 2noitSd cnea ,dednema t ,”cepxe “”,dullol”“c ,i,w ”“yas m“droew h tsesyu llarenegy npamo eCh.s Ttcepsord pn as,evitait,s iinevitcejbs ,oeigetatrs ,snal’py snpamoC g inkoo-dlrawro fyfitnedio r tette lredloherahss ih istn noisserpxer aliims dinam” da“ ”,netni,” “lan ”“e,ptaimts” e“,eveile”b,e “tipacitna“ l aicnad finnsa tnev eeurtf out tcepserh ti swwei vtnerrucs t in sotnemetatsg inkoo-ldrawrofe seh stes byanpamo eChs. Ttnemetats g inkoold-rawro feseh Ts.tnemetatg sinkoodl-rawro efhdi n tetcejore psoh tmoryf llaireta mreffidd luosc tulserl uatc .Aecnamrofrep , yctpurkn mbaorf ecnegremet nece ruro :sgihn treht gonomg,a indulci s,nnoitpumssda n aseitinatrecnu ,sksior tt cejbues r astnemetats thgier wehtm oor nfoititepmo; sceitinatrec nudna sksio rts su tcejbuds nsa ihpsnoitlaerd nsa seinsurb ut oceffy alesrevd adulohc cihw t hgied weviecrep ylbarova efromr oe vitceffe ero mfot nempoleveed hrt sotinpacitr ypatrsudi snsenllew dn hatlea hdn tanemeganam d n gainvlove yldipae rh ritn edea l aeo byt tilibra u; oesrb aebircsbus urwo od grinna ateo re tuintnoco e turliaf ur;o sdohte tmnemeganam s ecivres evitavon, inwe pnoleve ode tuintnooc yttilibaur t ;oekrasm sol thgied wnta nemegana mthgielw caiinl ecvititepmocy glinsearcin o tl eapp ao etuintnoo ct sdnarrb o stcudor ,specivreus ro fe ourliafe hr tos tcudorpd n saecivre sgintsixe rue ocnahnde n astcudorp dna ytilibuar o t;neimtner so sdnetr reumsnoc odt nopserr onoitubitrsidf solennahwc eon t dinnpaxye lfulsseccuos ty tilibt urar oo, ekram eht e ilptulm ssorcsa margor gpintekramd ng ainsitrevdaur ofy ocneiciffde nsa senevitceffe ehs t;evitaiti cinigetatrst nemelpi ymluflsseccu sot s,eesihcnarru fy obn ekat snoitcf ano oitatupeu rrno to cpae imhs;t mroftlap aidelm aicods ng aintekral matigi gdindulcs,i nmroftlap t nemiprati messf ao noitingoce reht ;sretnr rpaehtd on as,lanoisseforpe rcahtleah ’sCs ,Peititn reedivord petailiffs ,areilpup s,seesnecil f eihc rue;o crofkrow rue otavitod mnea ganay mlevitceffe o eturliaf rs otnatulsnor co sretnrpc aigetatrlen,s nosrey pe kfos soe lhst; egrahc y tilibur ago indulcs, ineurtne tvino rjo snoitaroblalo octr inetner osnoitisiuqc aeka ymllfusseccuos tytilibar uo; noitisnar treciffeo vitucexe larene nig nurtnwooa ddt etalesr eitinatrec un;sesseinsu hbcusf os tfieneb detipacitne ahe tzilear roe tarep eo,targetiy nlulfsseccu ost d n asffira istn egtnah ,cnemnoirvney ranoitflaig inntsix eehf t otulsea r s gaindulc,e incnedfinor cemusno cro snoitidnocc imonoce dnat iderc ehy it ntilitalodv esearci dnn atserlun aicod snl acaitilop fot cpali maitneto pehs, tetat rseretgi innsisr ,noisnete dag trintlacase tcpaei mh tg;introper laicnar finevol otrnocl anret einvitceffie natinamo etruliar fuo;s seinsubu rof e orutan lanoseas ehs;t tekral matipca f so uy nboitaimnrety lre eahs; trehtoh tiw ginrehtag mor felpoep edepr imo egaurocsi drso ecruose rginsseccae depi tmahts tnev efo ru fo o ecnedneped ehs ;tu o etlbarovae fr atah tsmre tn oos odo y ttilibaei nh rt ,osesnecilu ro fio natrecw enero t ytilibaei nhst; eseal etarene ogt ytiliba eht s;sednetbed eintare lbairav o etursopxer uof ot cpaei mh t;sredivor epcivre ystr-dpaihrnt o metsys stnemypa urof on oitarepo yrotcafsitse ah tgindrages reitinatrec s;nutnemeiruqery tidiquirl ehto ruyo fsitds ana tberd u oecivreos t hstc aneiciffus f o stsoce h tgindulcsi, nnrecnocy cavirp ros tc asuoicilar meht dons aehcear ybtiruce astad fto cpaie mh ;stmetsyrs o ygolonhcet ;s seinsuurb ieon cnegillet ilnaicfiitrea sdu nea target yinlfulsseccu os yttilibu ars; onoitgauled rnas way lcavirgp invlov ehti wecnailpmoc y it n nanemevlovui rnf oot cpai emh stal lews , ayllanoitanretdi nna yllcaitsemohd tob sthgiyr treporlp uatcelletr uine ocrofnoe t ytilibur ao o te ursopxru eo ot detaler sksisr; noitaluged rns awael rut dufnag intsix efto cpae imh; stthgi rytreporp luatcelletoi nt detaler simalc seitinatrecnud nsa ksis;r noitca yrotulgaer rno oitagiti flos emoctueo h;s tnoitlaguerd nas wl aercahtleah xelpmoc dnae visnetxe y cnerur cngierod fn a,ytreporp lautcelletlai, inclcoai, stilopc ,imonoce, yrotlague grindulc si,nnoitarep olanoitanretr uino hti wdetaicossa sdnedivid hsyc ad panas esahcrupe errahe i sngganoe t ytilibu ar o;msirorredt n ara fw toulse ars a detbarecax eeb yam sksi hrcihw s,ksir noitaroproci fno selcitr aru ison noisivorpr evoekat-itnda nsa redloherahts sivitc faos noitcea hot t detalers ksier; rutufe lbeaeseroe fhitn ehn; toitaroprocfi no selcitr aur si onnoisivormup ro fevisulcxe eh tdn asredloherahus r foso noitc eah totd etlaesr ksir;s wlay dbna e sohtg indulcsi ,neitinatrecnu dna sksi rrehtdo n aq;adsaN nok cot nsommocu rof og intsie lhitn atina omtl ia dfluoc ewt aht ytilibissop egnahcxdE nsa eitiurS echet hti wdelsfi tropecr idoire purie i onm to teim mtor dfeliate edsoht dna rette lredloherah ssihd i tnedulcin t e atisbewy ’snpamoeC ha tivd nav o.cge.sww twae sbaataR d eSGDA EECs’h tno elbaliav aerah ci“ Seh(w )”EChn( toissimmoC t natropy imnatm ah tdnatsred nuduloh suos. Ytnemetat gsinkood-lrawrof yna noe cnailer eudtnu u ptod nluohu so Y.m)o.cwwe.taroproc d i netseggurs d oesserpx eesoh tmoryf llairetam reffido sttluseyr s’npamoCe hte suc daluoi c,nere dhessucside soh gtindulcs, inrotcaf e seh etsiverr o etaduo ptn oitagilboy nea katredunt ons eod ynpamoCe ht, w laybd eirquesr t apecxt. Enemetats ginkool-drawrof yna o tr o rette rledloherahss iht foe tae dh rtetfrua ccot ahts ecnatsmucirc r sotnevre nooitamrofwi ne tncefle or sttnemetat gsinkool-drawrof erah cie ShC (wEhth tis wginl’sy finpamo eChw teive ortd esivde ar saredeaeR .siwrehtro sotneve detipacitnanu f eocnerrucce oh ttcefler m.) o.cww.etaropro cte atisbes’yw npamoe Cha tidv nv aocg.es.wwtw aesbaataR d eSADGs ’EECht neo lblaiava 81

fo serusaeM PAAG ot noitailicnoceR serusaeM laicnaniF PAAG-noN d etinU ehd int etpecc ayllarenes geilpcinrpg intnuocc ahti wecnadrocci dna etnesers ptulsedr etadilosnos ’cynpamo Cehtt nemelppu osT ehT .smetin iatrec tsujdra eodulcxet ahst tulser gintarepof oseurseal maicnaPfi nAAn-God nesolcsi dsahy npamoeC h P,)”tAAs“( GetatS noitazitromda n anoitaicerpes,d exta t,sereti enrofeb sginnr geaindulcsi ,neursealm aicna PfinAAG-nonr ettesl ihis n ttneser ypnpamoC in a g)r( aoef, lbcailppa sa,d etsujd AaDTIB ,dEetneserpd oireph cr eao dfn ;)aA”DTIB“( eEsnepx enoitsanepmo cdesb-earah sdn saesnepxe n)( ,coitazinagroe lraicnafi 1n1 retpaC sh'ynpamoCe ht dns aevitanretl caigetatrso dtetlaer stso ncoitcsanatt)b( , rbedf o tnemhsiguintxen o n oitcennoi sc nesnepxde( ) s,nlapg inurtcutrse r32d02 n4, a ,d2202520esolcsiyd lsuoiverep h thti wdetaicoss saegrah cginrutcutrsetr en ss aesso dln asinea ggnahcxgne iero fft ocpai emhs tha cus smetr ieht( )d oena, sretta mevitucexie natre cft onemegana emhth tiw e h T.A”)DTIB dEetsujdA(“s noitarep goinogno foe vitcaidt ino ner saeveilebt nemeganat mahwt olebs noitailicnocere hid ntetcaidin t cudorp dna ,sesnepxe evitatrsiidmnad n alareneg, ginlles, sesnepxe gintekrainm, grams sotgr, fior spsos rgtnesero psl yanpamoC e rehweslde edulcis nnoitailicnocee rh idtn etcaid irnehtru sf,s ametir aliimsr of stsujdta ahts isb PaAGAn-o a nnso esnepxt enempoleved . retter ledloherah ssihitn t natsno C.stluseP rAAGo t noitiddis na is ybacnerru ctnatsno anc os tluserl aicnas fintfi in oatrec stneseryp npamo Ceht n,oitiddIan ynpamoe Ch dT.oire-prev-odoirep tnatsnodc einamedr as hetar egnahcxe fs isa doirenp eewtes btulse srerpamoc noitamrofyi ncnerruc s.etaer gnahcx yecnerrucn giero rfeay-roirgp inss utulse rreay-tnerur gcintaulclyc ab ycnerurc tnatsnoc setaluclca e hft nooitualave' srotsevid nn astr ionf oitamrof linatnemelpupf ulses uedivorp seurseaml aicnafiP nGnA-Aoe nsehst eveile btnemeganaM .s seinsu bsy'npamoCe htf oe cnamrofree phf ts onosirpamod coire-prevd-ooirerp ouf flese urd ane acnamrofresp seinsubs y'npamoC n oitamrofis nih ,tsseinsubs’y npamoeC ht gintualavufi lne esue ras eursea mlaicnafi PnAA-nGoe nseht taht seveileb tnemegana emlihW laicna dfinetlaeer htr of etutitsbuss a a rn ooitlaos di ineredisno ceo bt tnea tmosn dinae rutal i nnatnemelppuss daeredisno ced bluohs d etli ytlraliimss a em seahte bt o ynasm erusea mlaicnafiP nn-AGAone seht, noitidd I.a nPA AGhti ewcnadroccdi a nerpaer pnoitamrofin redloherah ssih i t nseurseaM laicnainFP nAA-Go Nfso eursea PMAAoG tnoitailicnoce. SsR e eeinpamo rceht yo dbetropes reurseam o tseruseam laicnaP finnAG-Aoen h tfn ooitailicnoce rr ao rfettel redloherahss ihi ent rehwesled edulci, nyn fai ,snoitailicnocedr n arettel . serusea PmeAG Albarpamo cytlceird tsome ht t roff eelbanosearun tuohtid wedivorep bt onnec amocti ne no ktooltuo ADTIBdE etsujd Area lylug finkood-lrawroef h fto noitailicnoceA r y rsasecen smetgi intsujds auoiraev h tf tocpali maicnadfi nn aecnerrucceo h tgintscaeroy fletaurcc fa yotulciffi tdneree ihnhft o esucaeb e mse ah troF .detcideryp lbanoseare t bonlon rca,o trnocsy ’npamo eChf to tue or ad,erurccot eyt one vah tahnt oitailicnocer hcurs of n o tcpa ilmaireta ame va hdulo hccihw n,oitamrofei nlblaiava uenh tfo ecncafiigni eslbbaor pehts sessao t elban suiy npamoeC hst, nosear s. tulser laicna PfinAe GArutusf ti 19

scitsitatl SanoitarepO r e ePunevenR oitiprcsbu SylhtnodM nsaegatnecre tPpecxE s,dansuoh(IT n r) ebircsbu SegarevA d etiduanU rosseccSu dedE nshtnoMe erhTdeds nEhtnoe MerhT 3, 200r26 ebmetSpe2502 ,03r ebmetSpeecnairaVecnairaV y)cnerru CtnatsnoC()ycnerru CtnatsnoC( (1) srebircsb uSginmocIn srebircsbl uSaroivahegB imnocIn ,2912/A N,4030 2.6%)(4A/ N srebircsb lSucaiinl gCimnocIn197 AN/217 55%.7N/ A Inoc ginmSubrcsbisre94 2,8AN / 1,3761.42%)(N/ A (2) srebircsbu dSoireP f odEn srebircsbu lSaroivahed BoirePf d onE2,12 2N/ A22 86,9)%52.( /NA srebircsbulS caiinl dCoire Pf donE47 1/N A24 10.4% 4N A/ dEnoP freiod uSbrcsbisre2, 962/A N28,9 62)%13.(NA/ (3) rebircsbe SugarevrA e Peuneven Roitiprcsb SyulhtnoM rebircsb uSegarevrA e PeuneveRn oitiprcsbuSl aroivahe yBlhtnoM721 $.1 .$ 1726 $ 16.39 %5.0 %5.3 rebircsbS eugarevAr ee Puneve nRoitiprcsb SlucaiinlyC lhtnoM8562. $ 5 62.8$ 25 8$6. )%4.0(4%.(0) Mo ylhtnuSbrcsitipoR neveneu PrevA regae Subrcsbire1 2$1 .7$ 22.1 2$5 2 .81 14.3 %14.6% g. induno or etud umts o nya smlato: eTtoN t. ratsd oirenp evi g ats anoitarepdo enwo-ynpamois Cn rebircsbuSW W stropec ritresm” rebircsbu gSimnoceI “nhT) 1( d. ne doire npevi atg sanoitarepd oenw-oynpamosi Cn rebircsbS Wus Wtroperc itresm ”rebircsbd Suoire fPdo eEn“h T)2( egarevA ehy tbd edivisd ginreffos 'ynpamoe Ch tro sfnoitiprcsbu shtiwd etaicosss aee fylhtnoe mh tstrope rcitre”m rebircsbue Sgarev rAeeP uneven RoitiprcsbuyS lhtno“ eMhT )3( fr oebumen h tyd bedivi deuneveR noitiprcsbSus daetluaclcs as iseinsub evitcepserh ce raofs doirey plretr rauqo feuneveR noitiprcsbu ySlhtnoMs. esseinsu sbt rio frebircsbuS d oirefP do Ednna srebircsb gSuimnocIs ntfi o egarevea hs ts iseinsube vitcepsehr c reaofs doire pylretrqu arof ”rebircsbe uSgarevA“ ehTd. oirepy lretraqu evitcepse reh istn htnom .doire pylretre qauvitcepsere ht rofs rebircsbuS y cnerruCt antsno- eC uneveR detiduas) nU;egatnecreP tpecx ,sEdnasuoh(IT n rosseccSuaVrnaiec dednsE htno MeerhTdedEs nhtno eMerhT2602 vs.ycnerurt Cnatsno0 C622 2030 2r6,ebmetSpe025r 30, 2ebmetSpe5220vs. 2025 PAAGycnerrutC natsnoCPAGA (1) euneveR2 0,$1159 72$,51 3090,$71 211()12.%%9.0)(1 (2) euneven Roitiprcsbul SaroivaheB 1,1$32931,216 $841 $542 ,51.%52)1(.%)2(13 (3) Ceuneve nRoitiprcsb ulScaiinl$ 8, 0337 3 $ 87, 03 777 2$5,6.74 %% 647. (4) euneveRn oitiprcsbSu0 $561 ,91$153 32 2, ,$ 791290)(1%11.(10.)%9 (5) Oeuneve Rreht4 1 9 $ 7 9 4$ 2 , 11$6 0.1(%)9(18.5)% g. indnuo rote uum dst oyn a mslato Te:toN e. uneveRr ehtOd na euneve nRoitiprcsb uSf eotgaergg aeh ft ostsisnoce” uneve) R(1“ . sginreffol aroivaheBy s’npamoeC hrt osf noitiprcsbuh stid wetaicoss saee efht f sotsisnoc e”uneveR noitiprcsbu lSaroivahe“B)2 ( . sginreffl ocaiinlysC ’npamoeC hrt osf noitiprcsbush tiwd etaicossa seefe hf t sotsisnoce” uneveRn oitiprcsbul ScaiinlC )“3( . euneveRn oitiprcsbS lucaiinl dCne auneveRn oitiprcsb lSuaroivahe fBo ume shts i e”uneve Rnoitiprcsb)u4S “( e.uneve rrehtod ng aihnsilbu p,seitlayo drnsa nal ptnetmimmo co ttcepse rhti wsee efsihcnar g,finsnecilm or efuneve rfos tsisnoce” uneve Rreht )O“5( 02

A DTIBEd etsujdAo s) tsoL(e mocIt neN detiduanUs;) egatnecrePt pecxs ,EdansuohI(nT rosseccuS 26Q302 20262Q 2Q62100522 Q40Q2 325 s)so (eLmoctI neN$ 5 18 0 1, ,474 $1 02,0005( $) 5,8 33 $) ( $6557( ) 1, ingra M)ssoe L(moctI neN.9% 9.8%7 )%9.03(%3).6(43%3).( tseretIn,10168 11,58 811 475,11,7 6712, 520 sexaT62, 9101),(5115,2018 38)56(,18553,17 Dd nn aoitaicerpeAsesnepx nEoitazitrom5,031 02 6,951628,5 860, 32895,32 4 SesnepxEn oitsanepmo dCese-barah705 372866 046 — BEIADT$ 0,416 5 ,15$415,3 )$( 1 0 3 3$ 1 , 990 $ 33,168 EBTIADingra M3 .0%34.52 %.%9()16.8 %1%.3 9 (1) tD fbe tonemhsiugintxGE ni ona— ,461)2(— — — (2) stsoC noitcsanarT— — — (15)42 6,19 (3) segra CghinurtcutrseR— 16(5)4 688 ,4452 21 (4) stsoCd etlaee RvitucexE3 ,1918, 79356,3 1— — (5) rehtO(1)47(41)27(7)31)7(2 43 jdAetsud BEIADT 1,6605$ 3$96 74,$ (1,83)6$ 18,043 $ 2,7674 AdjE detsuBTIADingraM 3.3% 824.5 %1(%)1.11.1 %9 %4.2 g. indunoo rt eudmu ts ony a smlatoe T:toN . rf pa85%6. t oa ytilicao nFam Lrew Te Nst fion oitrop f ao 62y2 0at iM nnemypaery pratnulo vsy'npamo Ceh ftos tsisnoct be fd otnemhsiugintx)G1( en i noa . noitazingaroerl aicna1fi n1 retpa Cshy'npamo eChdt n saevitanretl caigetatro st detlae srtson coitcsana tgrinrruce-rnoin natreC)2 ( ylsuoiver ephte dulcis negrahcg inurtcutrse s.Rtnemngilea-c rigetatris natrecf otluse sra atunocdeain nh oitcudere hh ttiwd etaicossa sesnepxfe t osisnoc segrah gcinurtcutrseR )3( . nal pginurtcutrser 3d 202esolcsiy dlsuoiver peh tdnn alagp inrutcutrse r402d2 esolcsiyd lsuoiverep hn,t lag pinrutcutrse 5d0 2r2esolcsid s. retta mevitucexin eatre cfo tnemeganam eht htiw noitcenno iscn esnepxE4 )( s.noitcsanay trnpamocretni noy cnerrucng ieroff o tcpaei mhft o stsisno ycliraimr)P 5( 12

,sesnepxEt nempolevD tecudor s,Pesnepx Egintektrafi, Mors PsorG &) GSA( evitatrsdiimnA&l areg, GnienlSle detiduaUn ;s)egatnecreP tpecxE,s dansuoh(IT n rosseccuS 2203Q 652032 Q t cudorPl aregG ,nienlSlet cudorPl areg,G nienlSle s sorGg intekraMt nempolevDee vitatrsidinmA dnas soGrg intekraMt nempolevDee vitatrsidinm Adna tfiorPsesnepxEsesnepxEsesnepxEtfiorPsesnepxEsesnepxEsesnepxE PGAA$ 1 8,6920$ 33,094 32 55 ,$3483 9 ,$11,$1 41 28$ ,4044 055$ ,7202 ,1$ 6 eunevefR % o7.1 %1 %.126.43 %1 .2%21% .72.82%1 .4 %493% 4. Ajdsutmetns: (1) stsonC oitcsanarT— — — — — — — (9,261) Dd n naoitaicerpeAsesnepx Enoitazitrom5,353 — — (7,696),5315 — 5(8)(2,0301) (2) segrag ChinurtcutrseR— — — — 3 2— — (99) S-erahbesnepxn Eoitsanepmo dCesa0 (20)(99)(568)— — — — (3) stsoCd etlae eRvitucexE— (856)— 5(35)— — — — Tolat Ajdsutmetns5 3,54(875)(99)(168,8),515 8— (85)(55292,) Ajdsuted4,6$01 14 $ 92,2136$ 35 ,1 25,033 $ 6 299$,21 4$ 0448,9 ,42 7$0 ,759$3 eunevef Ro% %47.6 .211% .34 %.46% 1751. %%8. 21% .44%17.8 ycnerurCAdjtnetmsu334 40 2 91AN/ /NA N/A NA/ Constnat Cerurncy 600,2$9 11 $,4333 , 5723$,3388 6$ /AN N/A A/N NA/ eunevefR o%1.1% 7%1 26.34 .%.21% 2AN/ N/A /AN N/A Ajdsuted Constnat Cerurncy 8,30141 $3 5,2 $29, 8$ 513052$ 25 ,NA/ NA/ AN/ /NA euneveRf % o6 47.%.120 %43 .%631. %/NA /NA /AN A/N g. indunoor et uumd t so nyam slatoTe :toN n. oitazingaroe lraicnafi1 n1 retpaC shy'npamoe Ch dtnsa evitanretl caigetatrs otd etalers tsoc noitcsanag trinrrucen-roi nnatreC(1) . stnemgnile-arc igetatri snatre cfto lusera s taunocdea in hnoitcuder ehht tidw etaicosssa esnepxef o tsisno ,scnal pginrutcutrse rdesolcsidy lsuoivermp orf,s egrahcg inrutcutrse2) R( .srettae mvitucexine atrec ft onemeganaem ht htiw noitcenno sicn esnepx )E3( rosseccuS 2602 2QQ1 0262Q45022 t cudorPt cudorPt cudorP s soGrg intekraMt nempolevDes sorGg intekraMt nempolevDes sorGg intekraMt nempolevDe tfiorPsesnepxEsesnepxESG&AtfiorPsesnepxEsesnepxEGS&AtfiorPsesnepxEsesnepxESG&A PAGA 114,142 $5 47$,87 4, 4 $61$35 250,7,$ 61 182 9 $934,2 8,093 $ 48$08 ,451,4$ 019654,$ 478827$ , 82 6$ 58, eunevefR o%70% .32.95% .40% 13.0 %70.5% 55 .2%8.%4 2%.68 70. 1%40 %.25%4. .% 342 Ajdsutmetns: (1) stsoCn oitcsanarT— — — — — — — — — — — 5 41 D dnan oitaicerpeA noitazitrom sesnepxE,533 1— — (2,058)55,180 — — (2,0706),5305 — 5(9)(20,989) (2) eRtrsutcuinrg Chraegs— — — 15 6(6)5— — 5(33)1,1 86— — (2,966) Se-rahb noitsanepmo dCesa esnepxE0 (610)(109)(634)0 (411)(109)(364)— — — (604) (3) exEcuitev leRtadestso C— — — (3,978)— — — (1,563)— — — — TolatA jdsutmetns3, 532(160)(901)(90624,)1, 551(411)(910)(,23823),689 6— (95)(,29355) Ajdsuted 71 491,4$ $,715 7423 6,3$ $ 62, 256,32$ 7 871$,29 79 3 $ 879,448, 46$ 2 12 ,06$13 4$6,574 $8 1 83 , 28$337 , euneveRf o% .%367 29.4%%. 39158. %6 %3.755.1 %% 4.7 %48.1%4 .7440 .%25.4% 17 6%. g. indunoo re tu mdust oyn asm latoT e:toN n. oitazingaroer laicna fi1nr 1etpaCs h'ynpamoC eh dtnas evitanretl acigetatros d tetale srtsoc noitcsanat grinrurce-rnoinn atreC(1) ylsuoiverep h etdulcs inegrah cginrutcutrses. Rtnemngil-aer cigetatri snatre fc otluses ra atunocdea ni hnoitcude erhh ttidw etaicossa sesnepxfe ot sisno csegrahc ginurtcutrse )2R( 2d esolcsid0252n ,algp inurtcutrser 0242 dnn,a alg pinrutcutrser 0n. la pginurtcutrser3 2 s.rettae mvitucexien atrefc o tnemeganae mh thtiwn oitcennoi sn cesnepxE) 3( 22

s teeh eScanlad BetadilosnoC detidua;U)n sdansuoh(IT n rosseccuS 2062 ,03r ebmetSpe2502 ,1r 3ebmeDce SSSTEA SSSTEAT CUNRER stnelavique hsdc an hasaC 126,442 $, $69 2107 hs dcaetcitrseR6957 ,8 ,629 )156,1$ - 5202r,13 ebmed Dcne321 a ,-2$r6202 ,03 ebmet S:speecnawoll fao te( nselbavieceR11779, ,87136 sexate moc idnipaerP3, 7289780, ginsitrevdda n gaintekra dmipaerP50,2 0,75 92 stess tanerrur cehto dns aesnepxed ipaerP ,14891 3,1772 SSSTE TAUCL NERRATOT,4 81612062314, tte n,nemipuq den aytreporP1 6,63511, 8 Ostessa eseag lintarep 1803,,923 3 Glliwdoo,58 99180,312 05 Otes, ntessa elbignat rineht46,794 490664 4, sexat emoc idnerrefDe91 60,2,41826 Ostessa tnerrucnonr eht71 18,42 8154, SSSTE ALATOT$8 47 333,$ 9,46578 LIAIBLITINSAE DE QUITY T LCUNERRIAIBLITISE reaye nihno tiw eus deitilibaiel seal gintarep foon oitroP 981$0 261 ,$ Aelbays patnuocc,494 61129, 2 elbays paegadw n aseiralSa10020, 4375 3, Aginsitrevdda ng aintekra dmeurcc55,0 8,925 28 Atsereti dneurcc2 89408, 1 Oseitilibaild eurcca reht,19118 32904, Ielbay spaexat emocn4,6 146, 060 euneve rderrefDe9,1 4322, 5568 LT LUCNERRATOTIAIBLITISE9,1207 12,6563 Ltten, bemd retg-no,3947 02 664,564 Lseitilibaile sea glintarepo mregt-no11 95,3891, sexa etmoc idnerrefDe,6 23534023 1, Oseitilibai tlnerurcnon reht576 77 1 L LATOTIAIBLITIES55,0465 68682,7 EQUITY eulav r,p 0$akcots nommocr osseccSu;irohtu sae1 0,0ra00,h0 s0zde; 9,999 ta deussi serahs d n22 03r, 60a ebmetSpe9,993,r210 25 ebmeDt ce daeusss ierahs 28630 ,13 77,8737 Aed detualmuccfitic(819,43)(6,5092) Aemocs)i nsole( visneherpmor cehtod etluaumcc(1,595),1893 E LATOTQUITY29,38 6238,0171 LL ATOTIAIBLITINES ADE LATOT QUITY$48 73, 33$ 946,57 8 32

s noitarepf Oos tnemetatdS etadilosnoC detiduas;)U ntunom Aera rSheP tpecxE, sdnasuoh(In T rosseccSu dednsE htnoMe erhTdedEn shtnoe MerhT 262 ,03 r0ebmetSpe2502 ,03r ebmetSpe (1) tene ,uneve nroitiprcsbSu1 51,960 $,0$ 21 799 (2) te, enuneverr ehtO19 42116 , ten,e uneveR109,215 0 1,9127 (3) eunever noitiprcsbuf s tosoC4,1 444790,4 8 euneve rreht ofo tsoC 5627 euneverf t osoC4 90,24,47980 G ssorporfit108,6 29111,214 Mraksesnepx eginte3309,4 048, 44 Psesnepx tenempoleved tcudor52,3 5,7550 sesnepx eevitatrsiidmnda nla areneg,g inlSle338,9 4,6 1220 pOreating iocnme63,41 580,3 5 eIsnepxt eseretn8 16,01,2205 1 te ,ensnepx)e emocr( inehtO(714)324 Iocnm e(lsso) be rofeiocnmt exase5,28 00(,4359) Psexa etmoc rino nfoisivor 2,106953751, N teiocnm e(lsso)$ 5 ,1018 $ (75,516) aEnrings (t enlsso) p sreaher cisaB $1 .1 5 $ (5.67) Ddetuli$ 1.15 $ (5.67) Wehgietd arevgao cemm nsoahtstuo seranding cisaB99,99 7 899, Ddetuli2 1,0018 7,99 g. indnuo oret u dum sto ynas mlato Te:toN ’sy npamoCe htr ofs noitiprcsbu hsti wdetaicossa seefe h,te” uneveRn oitiprcsbuS laroivaheBt“ e )a(: nfoe tagerggea htf s otsisno”c ten e,uneve rnoitiprcsb1 ()S“u . sginreffl ocaiinl syC’npamoC eh rtosf noitiprcsbus htiwd etaicoss aseefe h ,”teuneveR noitiprcsbuS lcaiinl tC“e( )nbdn; asginreffl oaroivaheB e. uneve rreht donag ihnsilbus, peitlayod rnas nalp tnetmimmoco tt cepse hrti swee efsihcnarf,g insnecim lorfe uneve frso tsisno c”te en,uneverr ehtO) 2“( .secivrel scaiinl dCnl aaroivahes B'ynpamoe Ch rto fsesnepxeg intarepo dne aunevefr o tsocf s otsisno ce”unever noitiprcsbuf so tso“C) 3( 42

s wolF hsa Cfos tnemetatSd etadilosnoC d etidua )Uns;dansuohI(Tn rosseccSurossecederP dednsE htnoMe inNmor fdoirePmorfd oireP 002326 ,rebmetSpehguorh2 t0 5e 25,2nuJhguorh 4t 2r9,2 02ebmeDce 5202 03r, ebmetSpe4,252 02 eunJ :seitivitca gintareOp emoc) isnsot (leN1)(28 ,8$26()5$, 262811 3 ,10,1$ gintarepo )rofd es (yub dedivor hps ocae tmoc)si nso(l ten elicnocer ost tnetmsujdA s:eitivitca noitazitrom adnan oitaicerDpe8 415,67412 7,, 42011 tte, nnuocsidm)u imer pt(bedd na stsoc gincnadfi nerrefef don oitazitromA6(7)2)6(176 6, cs athgiIre sihcnarff t onemipramqdeiru— — ,75429 Ignol fto nemipram-stess adevil 3— 97 Serah-e noitsanepmoc desbaxesnep3, 142— 4 032, adt errefDexnoisivor p,1907 614,0 2236 ,2 ollAwstunocc ualftbuor do fecna48 35(1)(1)13,1 F eycnerurc gnieroxssoi)n l (agetaer gnahc620,1)(,1298 7 167, noN-tes, nmetni oitazinagroer hsca— — (1,176)523, Gen in oaxtbe dfo tnemhsiugint24(1),6— — Co:te udh s is ncaegnah Rselbaviece46,19 ()2425,8 ,042 Pde ipaerxsesnep,57133 39,9 431),2813( elbayps atunoccA0 ,6641, 5441378(,)2 seitilibai dleurccA8633)0(,326,1()448 1,05 euneve rderrefDe3,(697)2,(2)02(2,914) Ognol reht-te ns,eitilibail dns atess maret(191)()11(2)23,4 Iate mocnxse3(4,49),33194 5)315,0( Csahd edivor pyb (d esufro)seitivitc agintarepo ,32390 8,418 )34234,( Is:eitivitcga intsevn Ce latipaxserutidnep— 6)(7)8( Ctfo dsezilatipaw dn aerawt enempoleved etisbexserutidnep188,(99)3(,67)8(6,253) Ccra o fdi phasaqch ascf ao te,sn noitisiuqdeiru— ,1(20)0— Otes, nmetri eht— ()31)( Csahd es ufseitivitc agintsevi rno91(98,)80)(,4774(1,63) Fs:eitivitcga incnain Borrowytilicat fidergc invlover no sgin— — 13171,4 Fstsog cincnain— — 2,1(9)8 Pgnon l ostnemya-tbemd ret,8)0638(— — Taxes eraht se ond tetale drisp aettef o tnemelqya tiuwsdra— — )5(41 Cca rod fi hpasaqsnoitisiu— — 61,000() Csah ( desufro) dedivor pyb fiseitivitc gaincnan,(368)80— 153988, ffEe fo tcexhe scd an ahsn caos egnahec ta regnahcqhsc daetcitrse rdnsa tnelaviu1,)176(25 3,396 6 N te(esaerced)si eanc saerci nhsad cna h eqaviulsa dcetcitrsedr nsa tneh,43393)(,6493 0,11710 C ehsc danha saqdoirefp g oinninge ,hbsc daetcitrse drna stnelaviu5716,7 6 731620,5 06,52 Csahsad cna h eqaviulsad cetcitrserd nsa tneh,od ne fdoirep $ 812,233 $ ,771566 $ 073,621 52

noitamrofnI tcatnoC s rotsevIna ideM r elle eHtaK annA o ybas GasraileM mocc.inrci@srehctaWthgieWm oc.ww@oybasasri.aglem 62

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 EX-99.1 352.7 KB
• EX-99.2 EX-99.2 61.2 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 12.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.2 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 13.7 KB